Cover Page for Protocol 
 
Sponsor name:  Novo Nordisk A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN9924-4635 
Official title of study: Effic acy and safety of once-daily oral semaglutide 25 mg and 
50 mg compared with 14 mg in subjects with type 2 diabetes 
Document date: 16 September 2022 
*Document date refers to the date on which the document was most recently updated. 
 
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 1 of 93 
 
Protocol  
PIONEER PLUS 
NN9924-4635 
Including : 
Amendment 1, dated 09 November 2020 
Amendment 2, dated 04 March 2021 
Amendment 3, Croatia and Germany, dated 28 April 2021 
Amendment 4, dated 04 June 2021 
Amendment 5, dated 01 February 2022  
Amendment 6, dated 16 September 2022  
Protocol title:  
Efficacy and safety of once -daily oral semaglutide 25 mg and 50 mg compared with 14 mg in 
subjects with type 2 diabetes  
Substance: Semaglutide 
Universal Trial Number: U1111-1247-0210 
EudraCT Number: 2020-000299-39 
 
Trial phase:  3b 
 ;A523<99<D6;4%<C<%<?16@8	(.;16A@.33696.A2@D699/2@ A.A21.@K%<C<%<?16@8L  
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must  be restricted to relevant 
parties.  
 This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 2 of 93 
 
" $  $#%"( #$  
DOCUMENT HISTORY 
Document version Date Applicable in country(-ies) and/or 
site(s)  
Protocol version 7.0 (including 
protocol amendment no. 1, 2, 3, 4, 5 and 
6) 16 September 2022  Global 
Protocol version 6.0 (including 
protocol amendment no. 1, 2, 3, 4 and 
5) 01 February 2022 Global 
Protocol version 5.0 (including 
protocol amendment no. 1, 2, 3 and 4) 04 June 2021 Global 
Protocol version 4.0 (including 
protocol amendment no. 1, 2 and 3) 28 April 2021 For Croatia and Germany only 
Protocol version 3.0 (including 
protocol amendment no. 1  and 2) 04 March 2021 Global 
Protocol version 2.0 (including 
protocol amendment no. 1)  09 November 2020 Global 
Original protocol version 1.0 08 July 2020 Global 
Protocol version 7.0 (16 September 2022) 
This amendment is considered to be non-substantial based on the criteria set for th in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union,1 because 
it neither significantly impacts the safety nor ph ysical/mental integrity of subjects nor the scientific 
value of the trial. 
Overall rationale for preparing protocol, version 7.0: 
The overall rationale for the changes implemented in  the amended protocol is to add a description 
of the existing possibility to go back and eval uate previous ECG data in case of unforeseen or 
abnormal observations that could indicate safety findings and specify content and impact of the 
planned partial database lock. Furthermore,  a numerical error has been corrected in Table 9-2 . CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 3 of 93 
 
Section # and name Description of change Brief rationale 
8.2.3  Electrocardiograms Reason for central storage of ECG data has been 
provided. Bold  text added in below paragraph: 
M)52@D699/20<9920A213<?02;A?.9@A<?.42
for potential future assessment. This is to have 
the possibility to go back and evaluate previous ECG data in case of unforeseen or abnormal observations that could indicate 
safety 
findings or for future scientific 
purposes related to semaglutide, T2D, CV 
outcome or related diseases. N To clarify and describe the 
purpose of the ECG collection 
with the possibility of future evaluation.
 
9.2 Sample size determination The treatment difference (TD) for HbA 1cS-
point)  for the 50 mg dose has been corrected in 
the first five rows of the first column of Table
 9-2. To accommodate feedback from 
FDA: The TD was incorrectly 
stated here as -0.53 
9.5 Interim analyses Added reference to Section 9.7. To accommodate feedback from 
FDA.  
9.7 Reporting of the main part 
of the trial  Content and impact of the planned partial 
database lock have been specified before 
unblinding of data. To accommodate feedback from 
FDA.  
 CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 4 of 93 
 
  $$#  
 Page 
Protocol amendment summary of changes table ................................................................................... ........ 2  
Table of Contents.............................................................................................................. ................................ 4  
1 Protocol summary .............................................................................................................. ....................... 7  
1.1 Synopsis ...................................................................................................................... ..................... 7  
1.2 Flowchart ..................................................................................................................... .................. 10  
2 Introduction .................................................................................................................. ........................... 12  
2.1 Trial rationale ............................................................................................................... .................. 12  
2.2 Background .................................................................................................................... ................ 12  
2.3 Benefit-risk assessment ....................................................................................................... ........... 13  
2.3.1  Risk assessment ...............................................................................................................  13 
2.3.2  Benefit assessment ........................................................................................................... 16 
2.3.3  Overall benefit-risk conclusion ....................................................................................... 17  
3 Objectives and endpoints ...................................................................................................... .................. 18  
3.1 Primary and secondary objectives, and estimands ......................................................................... 18  
3.2 Primary and secondary endpoints ............................................................................................... ... 22  
3.2.1  Primary endpoint ............................................................................................................. 22 
3.2.2  Secondary endpoints ........................................................................................................ 22  
3.2.2.1  Confirmatory secondary endpoints ................................................................. 22  
3.2.2.2  Supportive secondary endpoints ..................................................................... 22  
4 Trial design .................................................................................................................. ............................ 23  
4.1 Overall design ................................................................................................................ ................ 23  
4.2 Scientific rationale for trial de sign ......................................................................................... ........ 23  
4.3 Justification for dose ........................................................................................................ .............. 24  
4.4 End of trial definition ....................................................................................................... .............. 25  
5 Trial population .............................................................................................................. ......................... 26  
5.1 Inclusion criteria ............................................................................................................ ................ 26  
5.2 Exclusion criteria ............................................................................................................ ............... 26  
5.3 Lifestyle considerations ...................................................................................................... ........... 27  
5.3.1  Meals and dietary restrictions .......................................................................................... 27  
5.4 Screen failures ............................................................................................................... ................. 28  
5.5 Run-in criteria and randomisation criteria and dosing day criteria ................................................ 28  
6 Treatments .................................................................................................................... ........................... 29  
6.1 Treatments administered ....................................................................................................... ......... 29  
6.2 Preparation/handling/storage/accountability .................................................................................. 31 
6.3 Measures to minimise bias: Ra ndomisation and blinding ............................................................. 32  
6.4 Treatment compliance .......................................................................................................... .......... 33  
6.5 Concomitant medication ........................................................................................................ ........ 33  
6.5.1  Rescue medication ........................................................................................................... 3 4 
6.6 Dose modification ............................................................................................................. ............. 34  
6.7 Treatment after end of trial .................................................................................................. .......... 34  
7 Discontinuation of trial treatment and subject discontinuation/withdrawal ..................................... 35  
7.1 Discontinuation of trial treatment ............................................................................................ ...... 35  
7.1.1  Temporary discontinuation of trial treatment .................................................................. 36  
7.1.2  Rescue criteria ............................................................................................................... .. 36 
7.2 Subject discontinuation/withdrawal from the trial ......................................................................... 36  
7.2.1  Replacement of subjects .................................................................................................. 37  
7.3 Lost to follow-up ............................................................................................................. .............. 37  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 5 of 93 
 
8 Trial assessments and procedures .............................................................................................. ........... 38  
8.1 Efficacy assessments .......................................................................................................... ............ 39  
8.1.1  Clinical efficacy laboratory assessments ......................................................................... 39  
8.1.2  Body weight.................................................................................................................... . 39 
8.1.3  Waist circumference ........................................................................................................ 39  
8.2 Safety assessments ............................................................................................................ ............. 39  
8.2.1  Physical examinations ..................................................................................................... 40  
8.2.2  Vital signs ................................................................................................................... ..... 40  
8.2.3  Electrocardiograms .......................................................................................................... 4 0 
8.2.4  Eye examination .............................................................................................................. 41 
8.2.5  Clinical safety laboratory assessments ............................................................................ 41  
8.3 Adverse events and serious adverse events .................................................................................... 42 
8.3.1  Time period and frequency for collecti ng AE and SAE information .............................. 42  
8.3.2  Method of detecting AEs and SAEs ................................................................................ 43  
8.3.3  Follow-up of AEs and SAEs ........................................................................................... 43  
8.3.4  Regulatory reporting requirements for SAEs .................................................................. 43  
8.3.5  Pregnancy ..................................................................................................................... ... 43  
8.3.6  Cardiovascular and death events ..................................................................................... 43  
8.3.7  Technical complaints ....................................................................................................... 44  
8.4 Treatment of overdose ......................................................................................................... .......... 44  
8.5 Pharmacokinetics .............................................................................................................. ............. 44  
8.6 Pharmacodynamics .............................................................................................................. .......... 44  
8.7 Genetics ...................................................................................................................... ................... 45  
8.8 Biomarkers .................................................................................................................... ................. 45  
8.9 Immunogenicity assessments .................................................................................................... ..... 45  
8.10  Health economics .............................................................................................................. ............. 45  
9 Statistical considerations .................................................................................................... .................... 46  
9.1 Statistical hypotheses ........................................................................................................ ............. 46  
9.2 Sample size determination ..................................................................................................... ........ 47  
9.3 Populations for analyses ...................................................................................................... .......... 49  
9.4 Statistical analyses .......................................................................................................... ............... 51  
9.4.1  General considerations .................................................................................................... 51  
9.4.2  Primary endpoint ............................................................................................................. 52 
9.4.3  Secondary endpoints ........................................................................................................ 53  
9.4.3.1  Confirmatory secondary endpoint ................................................................... 53  
9.4.3.2  Supportive secondary endpoints ..................................................................... 53  
9.4.4  Other safety analyses ....................................................................................................... 5 4 
9.4.5  Other analyse(s) .............................................................................................................. . 54 
9.4.5.1  Pharmacokinetic modelling ............................................................................. 54  
9.5 Interim analyses .............................................................................................................. ............... 54  
9.6 Data monitoring committee ..................................................................................................... ...... 54  
9.7 Reporting of the main part of the trial........................................................................................ .... 54  
10 Supporting documentation and operational considerations ............................................................... 56  
10.1  Appendix 1: Regulatory, ethical, and trial oversight considerations ............................................. 56  
10.1.1  Regulatory and ethical considerations ............................................................................. 56  
10.1.2  Financial disclosure ......................................................................................................... 56 
10.1.3  Informed consent process ................................................................................................ 56  
10.1.4  Information to subjects during trial ................................................................................. 57  
10.1.5  Data protection ............................................................................................................... . 57 
10.1.6  Committees structure ....................................................................................................... 58  
10.1.6.1  Novo Nordisk safety committee...................................................................... 58  
10.1.7  Dissemination of clinical trial data .................................................................................. 58  
10.1.8  Data quality assurance ..................................................................................................... 58  
10.1.8.1  Case report forms ............................................................................................ 58  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 6 of 93 
 
10.1.8.2  Monitoring ...................................................................................................... 59  
10.1.8.3  Protocol compliance ........................................................................................ 59  
10.1.9  Source documents ............................................................................................................ 5 9 
10.1.10  Retention of clinical trial documentation ........................................................................ 60  
10.1.11  Trial and site closure ....................................................................................................... 60 
10.1.12  Responsibilities............................................................................................................... . 61 
10.1.13  Indemnity statement ........................................................................................................ 61  
10.1.14  Publication policy ............................................................................................................  62 
10.1.14.1  Communication of results ............................................................................... 62  
10.1.14.2  Authorship ....................................................................................................... 62  
10.1.14.3  Site-specific publication(s) by investigator(s)................................................. 63  
10.1.14.4  Investigator access to data and review of results ............................................ 63  
10.2  Appendix 2: Clinical laboratory tests ......................................................................................... ... 64  
10.3  Appendix 3: Adverse events: Definitions and procedures for recording, evaluation, follow-
up, and reporting ............................................................................................................. ............... 66  
10.3.1  Definition of AE ..............................................................................................................  66 
10.3.2  Definition of an SAE ....................................................................................................... 66  
10.3.3  Description of AEs requiring a dditional data collection ................................................. 67  
10.3.4  Recording and follow-up of AE and/or SAE ................................................................... 69  
10.3.5  Reporting of SAEs ........................................................................................................... 7 0 
10.4  Appendix 4: Contraceptive guidance and co llection of pregnanc y information ............................ 72  
10.5  Appendix 5: Technical complaints: Definition and procedures for recording, evaluation, 
follow-up and reporting ....................................................................................................... .......... 76  
10.5.1  Definition of technical complaint .................................................................................... 76  
10.5.2  Recording and follow-up of technical complaints ........................................................... 76  
10.5.3  Reporting of technical complaints ................................................................................... 77  
10.6  Appendix 6: Hypoglycaemic episodes ........................................................................................... 78 
10.7  Appendix 7: Retention of human biosamples ................................................................................ 80  
10.8  Appendix 8: Country-specific requirements .................................................................................. 81  
10.9  Appendix 9: Abbreviations ..................................................................................................... ....... 83  
10.10  Appendix 10: Protocol amendment history ................................................................................... 86  
11 References .................................................................................................................... ............................ 92  
 
Protocol attachment I Global list of key staff and relevant departments and suppliers 
Protocol attachment II Country list of key staff and relevant departments. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 7 of 93 
 
1 " $  #%"(  
1.1 Synopsis 
Rationale 
The currently approved oral semaglutide maintenance doses are 7 mg and 14 mg2, and the approval 
was based on the comprehensive global clinical phase 3a development programme (the PIONEER 
programme). Although oral semaglutide provided clinically relevant benefits for subjects with type 
2 diabetes (T2D) at all disease stages in the PIONEER programme, approximately 20-40% of the 
subjects did not achieve the recommended level of glycaemic control (HbA 1c <7%). Oral 
semaglutide dose levels higher than 14 mg may enable such subjects to achieve adequate glycaemic 
control. 
Dose-dependent effects of oral semaglutide at doses exceeding the currently maximum approved 
dose for the treatment of T2D (14 mg once daily), have been demonstrated in relation to glycaemic 
control and body weight (NN9924-3790). The 40 mg dose level reduced HbA 1c by 1.9 %-points and 
body weight by 7 kg.  
To support the approval of higher dose levels of oral semaglutide in T2D, the present randomised 
controlled clinical trial is designed to compare the efficacy, safety and tolerability of oral 
semaglutide 14 mg, 25 mg and 50 mg in subjects with T2D.  
Objectives and endpoints 
Primary 
objective To confirm superiority of oral semaglutid e 25 mg and 50 mg once daily versus oral 
semaglutide 14 mg once daily on HbA 1c reduction in subjects with T2D on stable 
dose of 1-3 OADs. 
Secondary 
objectives To confirm superiority of oral semaglutid e 25 mg and 50 mg once daily versus oral 
semaglutide 14 mg once daily on body weight reduction in subjects with T2D on a 
stable dose of 1-3 OADs. 
To compare the efficacy of oral semaglutide 25 mg and 50 mg once daily versus 
oral semaglutide 14 mg once daily on parameters related to glycaemic control in subjects with T2D on a stable dose of 1-3 OADs. 
To compare the efficacy of oral semaglutide 25 mg and 50 mg once daily versus 
oral semaglutide 14 mg once daily on parameters related to weight -related 
outcomes in subjects with T2D on a stable dose of 1-3 OADs. 
To compare the safety and tolerability of oral semaglutide 25 mg and 50 mg once 
daily versus oral semaglutide 14 mg once daily in subjects with T2D on stable 
dose of 1-3 OADs. 
Estimands 
For the primary and the confirmatory secondary objective, estimands of primary interest and 
additional estimands are defined. The estimands are used to address the trial objectives in terms of 
two different aspects of the treatment effect of oral semaglutide 14, 25 and 50 mg.  
The primary and secondary estimands address the primary questions of interest: What is the 
efficacy of oral semaglutide 25 and 50 mg versus oral semaglutide 14 mg on change from baseline 
to week 52 in HbA 1c (primary objective) and body weight (confirmatory secondary objective) in CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 8 of 93 
 
subjects with T2D on stable dose of 1-3 OADs re gardless of treatment discontinuation, changes in 
dose and initiation of additional anti-diabetic medication. 
The additional estimands address additional questions of interest: What is the efficacy of oral 
semaglutide 25 and 50 mg versus oral semaglutide 14 mg on change from baseline to week 52 in 
HbA 1c (primary objective) and body weight (confirmatory secondary objective) in subjects with 
T2D on stable dose of 1-3 OADs regardless of change in dose of trial treatment and if all subjects 
had remained on trial treatment without use of rescue medication.  
Similar estimands are defined for the other secondary efficacy objectives. 
Primary endpoint 
Endpoint title Timeframe Unit 
Change in glycated haemoglobin (HbA 1c) From baseline (week 0) to week 52 %-point 
Secondary confirmatory endpoint 
Endpoint title Timeframe Unit 
Change in body weight  From baseline (week 0) to week 52 kg 
Supportive secondary endpoints 
Endpoint title Timeframe Unit 
Change in fasting plasma glucose (FPG) From baseline (week 0) to week 52  mmol/l 
Achievement of HbA 1c <7% (Yes/No)  At week 52 Count of subjects 
Achievement of HbA 1c H-2@	%<  At week 52 Count of subjects 
Relative change in body weight  From baseline (week 0) to week 52 Percentage (%) 
Change in waist circumference From baseline (week 0) to week 52 cm 
0562C2:2;A<3D2645A9<@@I-2@	%<  At week 52 Count of subjects 
0562C2:2;A<3D2645A9<@@I
-2@	%<  At week 52 Count of subjects 
Adverse events From baseline (week 0) to follow-up visit 
(week 73) Count of events 
Overall design 
This is a 68-week, randomised, active-control led, double-blinded, three-armed, multi-centre, 
multinational clinical trial comparing the efficacy , safety and tolerability of once-daily oral 
semaglutide 25 mg, 50 mg and 14 mg (the current maximum maintenance dose) in subjects with 
T2D, on stable doses of 1-3 oral anti-diabetic drugs (OADs) (metformin, sulfonylureas, SGLT2 
inhibitors, DPP-4 inhibitors). 
Subjects will be randomised to receive maintenance doses of either 14 mg, 25 mg or 50 mg oral 
semaglutide once daily. Randomisation will be stra tified on baseline oral anti-diabetic medication 
and will include a total of 8 strata for combinat ions of sulfonylureas, SGLT2 inhibitors, and 
terminated DPP-4 inhibitors. Metformin is  not included in the stratification. 
Key inclusion criteria 
 Male or female, age above or equal to 18 year s at the time of signing informed consent. 
 6.4;<@21D6A5AF=216./2A2@:2996AB@I  180 days prior to the day of screening. 
 HbA 1c of 8.0- 
P::<9	:<9/<A56;09B@6C2  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 9 of 93 
 
 $ I 5 kg/m2. 
 Stable daily dose(s) for 90 days prior to the day of screening of: any of the following treatment 
regimens: 
- No more than 3 of the following oral anti-diabetic drugs and at least 1 marked with a *: 
o * $2A3<?:6;I

:4<?:.E6:B:A<92?.A21<?23320A6C21<@2  
o * (B93<;F9B?2.@(*I5.93<3A52:.E6:B:.==?<C211<@2.00<?16; 4A<9<0.99./29
or maximum tolerated or effective dose). 
o * SGLT2 inhibitors (maximum tolerated dose). 
o DPP-4 inhibitors (maximally indicated dose as per local label). 
 Subjects, on treatment with stable dose of DPP-4 inhibitors at inclusion, must be willing to 
terminate DPP-4 inhibitor treatment at randomisation (with no wash-out).  
Key exclusion criteria 
 Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed. 
 Renal impairment measured as estimated glomer ular filtration rate (eGFR) value of <30 
mL/min/1.73 m
2 according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
creatinine equation as define d by KDIGO 2012 classification. 
 Uncontrolled and potentially unstable diabetic re tinopathy or maculopathy. Verified by a fundus 
examination performed within the past 90 days prior to screening or in the period between 
screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a 
digital fundus photography camera specified for non-dilated examination. 
Number of subjects 
1620 subjects will be randomly assigned to trial treatment.  
Treatment groups and duration 
The planned total duration for each subject will be approximately 75 weeks. The trial includes a 
screening period of approximately two weeks followed by randomisation. Oral semaglutide will be 
dosed once daily starting with a dose escalation period of up to 16 weeks followed by a 
maintenance period of minimum 52 weeks. The duration of dose escalation period will depend on 
the maintenance dose to be re ached, but the total dose escalation and maintenance period comprises 
68 weeks for all three treatment arms. All subject s will enter a 5-week follow-up period after the 
end-of-treatment visit. 
Tablets of oral semaglutide (3 mg, 7 mg, 14 mg, 25 mg, 50 mg) in dose packs and/or HDPE bottles 
will be provided by Novo Nordisk A/S. 
The trial products will not be available to subjects after the end of trial. 
Trial data monitoring committee: No CONFIDENTIAL
Protocol       Date: 16 September 2022 Status:  Final  Novo Nordisk 
Trial ID: NN9924-4635       Version: 7.0 Page: 10 of 93 
 
1.2 Flowchart   Protocol sections Screening  Randomisation 
Dose escalation/ 
maintenance period  Maintenance period End of treatment Follow-up  
Visit   V1 V2 V3 V4 V5 P6 V7 P8 V9 V10 V11 V12 V13 V14 V15 V16 V17 
Timing of Visit   -2W 0W 4W 8W 12W 14W 16W 18W 20W 26W 32W 38W 44W 52W 60W 68W 73W 
Visit Window (Days)   Â±7 Â±0 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 +3 
  Informed Consent and Demography a 10.1.3  X                 
  Eligibility Criteria  5.1,5.2 X X                
  Randomisation    X                
  Discontinuation Criteria  7.1   X X X X X X X X X X X X X   
  Concomitant Medication  6.5 X X X X X X X X X X X X X X X X X 
  Medical History/Concomitant Illness  8.2 X                 
  Tobacco Use b   X                 
  Pregnancy Test c  8.3.5 ,10.4 X               X X 
  Height  8.2.1 X                 
  Body Weight  8.1.2 X X X X X  X  X X X X X X X X  
  Waist circumference  8.1.3  X        X    X  X  
  ECG 8.2.3  X        X      X  
  Adverse Event  8.3,10.3 X X X X X X X X X X X X X X X X X 
  Hypoglycaemic Episodes  10.6  X X X X X X X X X X X X X X X X 
  Laboratory Assessments 10.2 X X X X X  X  X X X X X X X X X 
  Attend Visit Fasting 5.3.1   X X  X  X   X    X  X  
  PK Sampling  8.5   X  X  X   X    X  X  
  Eye Examination 8.2.4 X             X  X  
  Physical Examination  8.2.1 X             X  X  
  Vital Signs  8.2.2 X X X X X  X  X X X X X X  X  
  Dispensing Visit 6.1, 6.3, 5.3.1   X X X X  X  X X X X X X X   
Protocol       Date: 16 September 2022 Status:  Final  Novo Nordisk 
Trial ID: NN9924-4635       Version: 7.0 Page: 11 of 93 
   Protocol sections Screening  Randomisation 
Dose escalation/ 
maintenance period  Maintenance period End of treatment Follow-up  
Visit   V1 V2 V3 V4 V5 P6 V7 P8 V9 V10 V11 V12 V13 V14 V15 V16 V17 
Timing of Visit   -2W 0W 4W 8W 12W 14W 16W 18W 20W 26W 32W 38W 44W 52W 60W 68W 73W 
Visit Window (Days)   Â±7 Â±0 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 +3 
  Drug Accountability 6.4  X X X X  X  X X X X X X X X  
  IWRS Session   X X X X X  X  X X X X X X X X  
  Hand Out ID Card   X                 
  Hand Out and Instruct in Diary  8 X X X X X  X  X X X X X X X X  
  Hand Out and Instruct in BG-meter  10.6  X                
  Hand Out of Urine Kit d  10.2 X   X     X    X  X   
  Hand Out of Pregnancy Test 8.3.5 , 10.4  X                
Footnotes:  
a: Demography consists of year of birth, sex, race and ethnicity (according to local regulation) 
b: Tobacco use is defined as smoking at least one cigarette or equivalent daily. 
c: For women of childbearing potential only. In addition to the planned assessment at sc reening, end of treatment and follow-up,  urine dipstick pregnancy test should be performed at any 
time during the trial if a menstrual peri od is missed, or if pregnancy is susp ected, or as required by local law. 
d: This urine kit can be handed out at an earlier visit for su bjects who discontinue trial treatment prematurely and do not atte nd the V15 visit. 
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 12 of 93 
 
2 
$" %$   
Semaglutide is a potent glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a high degree of 
homology to human GLP-1. GLP-1 RAs are recommende d for the treatment of patients with type 2 
diabetes (T2D) with inadequate glycaemic control and a need to minimize weight gain, promote 
weight loss or minimize hypoglycaemia.3 Guidelines have recently been updated to recommend 
GLP-1 RAs for patients with T2D and high cardi ovascular (CV) risk, esta blished cardiovascular 
disease (CVD), or chronic kidney disease (CKD).4 
Oral semaglutide (RybelsusÂ®) is the first peptide-based anti-diabetic therapy available for oral 
administration. Based on a comprehensive glob al clinical development programme (PIONEER), 
once-daily oral semaglutide at dose levels 3, 7 an d 14 mg was recently approved as an adjunct to 
diet and exercise to improve glycaemic control in adults with T2D. 
In addition, semaglutide is approved as a subcutaneous (s.c.) formulation (OzempicÂ®, NN9535, 
based on the global clinical phase 3a programme SUSTAIN) for once-weekly administration for the 
treatment of T2D and reduction of CV risk in patients with T2D and established CV disease. 
2.1 Trial rationale 
The currently approved oral semaglutide maintenance doses are 7 mg and 14 mg2. Although oral 
semaglutide provided clinically relevant benefits for subjects with T2D at all disease stages, 
approximately 20-40% of the subjects in the PIONEER programme did not achieve the 
recommended level of glycaemic control (HbA 1c <7%). Oral semaglutide dose levels higher than 
14 mg may enable such subjects to achieve adequate glycaemic control. 
Dose-dependent effects of oral semaglutide, at doses exceeding the currently maximum 
maintenance dose for the treatment of T2D, have been demonstrated in relation to glycaemic 
control and body weight (trial NN9924-3790). 
To support the approval of higher dose levels of oral semaglutide in T2D, the present randomised 
controlled clinical trial is designed to compare the efficacy, safety and tolerability of oral 
semaglutide 14 mg, 25 mg and 50 mg in subjects with T2D. See Section 4.3 for details on the 
justification of dose. 
2.2 Background 
The PIONEER programme was a comprehensive clinical programme and including 10 phase 
3a trials comprising 9,543 subjects with T2D,  of whom 5,707 were exposed to oral semaglutide. 
The programme confirmed a favourable benefits/risk profile of oral semaglutide in a broad and 
representative population of subjects with T2D, ranging from treatment-naÃ¯ve to insulin-requiring subjects, subjects with micro- and macrovascular  disease and subjects with moderate renal 
impairment. Clinically relevant and sustained improve ments in glycaemic control and reductions in 
body weight were demonstrated with the approved maintenance doses of oral semaglutide, and the 
safety and tolerability profiles of oral semaglut ide were consistent with those of other GLP-1 RAs.
5 
By week 26 in the PIONEER phase 3a programme, oral semaglutide 14 mg had reduced HbA 1c by 
up to 1.4% and body weight by 4.4 kg and enabled around 60-80% of the subjects to achieve 
HbA 1c <7%5. At week 52, the proportion of subjects who had achieved HbA 1c <7% was similar to CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 13 of 93 
 
that at week 26. Hence, 20-40% of subjects had not achieved the recommend glycaemic goal by 
week 26 or 52.  
Dose-dependent reductions in HbA 1c and body weight with oral semaglutide at dose levels up to 
40 mg (i.e. around 3 times the currently approved maximum dose level) were demonstrated in the 
oral semaglutide dose-finding phase 2 trial (NN9924-3790). The 40 mg dose level reduced HbA 1c 
by 1.9 %-points and body weight by 7 kg.  
The proportion of subjects with adverse events (AEs) and the number of AEs increased with 
increasing oral semaglutide dose in trial NN9924-3790. The proportion of subjects who 
discontinued treatment prematurely due to an AE was higher with oral semaglutide compared to 
placebo and appeared to increase with increasing  dose of oral semaglutide. The AEs were mainly 
gastrointestinal (GI) AEs; however, most were tr ansient and mild to moderate in severity. A low 
starting dose of oral semaglutide and slow dose escalation were associated with lower rates of 
GI AEs during dose escalation and he nce lower treatment discontinuation J initiating treatment with 
a low dose of oral semaglutide had a greater ef fect on mitigating GI AEs than a slow dose 
escalation, which is why dose escalation at a starting dose of 3 mg was implemented in the 
PIONEER programme. The rate of SAEs was low across oral semaglutide groups, and no fatal events were reported in any treatment group in the NN9924-3790 trial. Thus, although the 
frequency of GI AEs also appeared to be dose dependent, all dose levels investigated in trial 
NN9924-3790 (including 40 mg) were found to be sa fe and well tolerated, and no unexpected safety 
concerns were identified.  
A comprehensive review of results from the nonclini cal and clinical studies of oral semaglutide can 
/23<B;16;A520B??2;A216A6<;<3A526;C2@A64.A<?N@/?<05B?2
5, and any updates hereof. 
2.3 Benefit-risk assessment 
Main benefits and risks are described in the below sections. More detailed information about the 
known and expected benefits and risks and reasonably expected adverse events (AEs) of oral 
semaglutide :.F/23<B;16;A526;C2@A64.A<?N@/?<05B?25, prescribing information2 or summary of 
product characteristics.6  
2.3.1 Risk assessment 
Potential risk of 
clinical 
significance  Summary of data/rationale for risk  Mitigation strategy 
Trial treatment (semaglutide) 
Gastrointestinal 
(GI) disorders  Consistent with other GLP-1 RAs, the most 
frequent AEs with semaglutide are GI 
(nausea, vomiting and diarrhoea). In general, these reactions are mild or moderate in severity, of short duration, and dose dependent.  
 
 
In subjects treated with GLP -1 RAs, 
nausea, vomiting and diarrhoea may lead to 
significant dehydration. This should be considered when treating subjects with impaired renal functio n as it may cause a 
deterioration of renal function.  Clinical trials have shown that a low starting 
dose and gradual dose escalation mitigate the 
risk of developing GI symptoms.  
 
Subjects with GI symptoms are recommended to drink plenty of fluids to avoid volume depletion. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 14 of 93 
 
Potential risk of 
clinical 
significance  Summary of data/rationale for risk  Mitigation strategy 
Trial treatment (semaglutide) 
Hypoglycaemia There is a low risk of hypoglycaemic 
episodes when semaglutide is used as monotherapy. Subjects treated with 
semaglutide in combination with 
sulfonylurea or insulin may have an increased risk of hypoglycaemia.  The risk of hypoglycaemia can be lowered by 
reducing the dose of sulfonylurea or insulin when initiating treatment with semaglutide.
 
 
Diabetic 
retinopathy complications  A 2-year clinical trial with s.c. semaglutide 
(NN9535 -3744) investigating 3,297 
subjects with T2D, high CV risk, long 
duration of diabetes and poorly controlled 
blood glucose . In this trial, adjudicated 
events of diabetic retinopathy 
complications occurred in more subjects treated with s.c. semaglutide (3.0%) compared to placebo (1.8%). 
This was 
observed in insulin -treated subjects w ith 
known diabetic retinopathy. The treatment 
difference appeared early and persisted 
throughout the trial. Systematic evaluation of diabetic retinopathy complication was only performed in the CV outcomes trial 
with s.c. semaglutide. In clinical trials with 
oral semaglutide of up to 18 months duration involving 6,352 subjects
 with 
T2D, adverse event related to diabetic 
retinopathy were reported in similar 
proportions in subjects treated with 
semaglutide (4.2%) and comparators 
(3.8%).  Rapid improvement in glucose control has been 
associated with a temporary worsening of diabetic retinopathy, but other mechanisms 
cannot be excluded. Long
-term glycaemic 
control decreases the risk of diabetic retinopathy. 
These subjects should be monitored closely and treated a
ccording to clinical guidelines.  
 
Subjects with uncontrolled and potentially unstable diabetic retinopathy or maculopathy 
will not be enrolled in this trial.
 
Allergic reactions As with all protein-based pharmaceuticals, 
treatment with semaglutide may evoke allergic reactions, including serious allergic reactions such as 
angioedema and 
anaphylactic reactions.  As a precaution, subjects with known or 
suspected hypersensitivity to s emaglutide or 
related products will not be enrolled in this trial. 
In addition, subjects will be instructed to contact the site staff as soon as possible for further 
guidance if suspicion of a hypersensitivity 
reaction to the trial product occurs. 
Acute pancreatitis Acute pancreatitis has been observed with 
the use of GLP -1 RAs. In the completed 
phase 3 trials with s.c. semaglutide and oral 
semaglutide, both the event rate and the 
proportion of subjects experiencing 
confirmed pancreatitis were similar with 
semaglutide and comparator. Few events 
were confirmed; the events occurred throughout the trial periods and the overall rates were similar to the rates reported in 
background populations. Subjects should be informed of the characteristic 
symptoms of acute  pancreatitis and if 
pancreatitis is suspected, semaglutide should be 
discontinued. If confirmed, semaglutide should 
not be restarted.  
Neoplasms 
(malignant and non
-malignant) Patients with T2D, as well as patients with 
overweight or obesity, have an increased risk of certain types of cancer. There is no evidence from clinical trials that GLP
-1-
based therapies increase the risk of 
neoplasms. However, in the s.c. 
semaglutide as well as oral semaglutide 
phase 3a trials, the proportion of subjects with neoplasms (malignant and non-Subjects with presence or history of malignant 
neoplasm within 5 years prior to the day of screening will not be enrolled in this trial. Basal and s
quamous cell skin cancer and any 
carcinoma in -situ is allowed CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 15 of 93 
 
Potential risk of 
clinical 
significance  Summary of data/rationale for risk  Mitigation strategy 
Trial treatment (semaglutide) 
malignant) were slightly higher with 
semaglutide than with comparator. The number of subjects exposed to 
s.c. 
semaglutide or oral semaglutide for a 
longer  period is considered insufficient for 
a thorough assessment of the risk of neoplasms. 
Pancreatic cancer Patients with T2D have an increased risk of 
certain types of cancer such as pancreatic 
cancer. There is currently no support from 
non-clinical studies, clinical trials or post-
marketing data that GLP- 1 based therapies 
increase the risk of pancreatic cancer. However, pancreatic cancer has been classified as a potential class risk for all marketed GLP
-1 RAs by regulatory 
agencies. There is no indication of an 
increased relative risk in the semaglutide treatment groups vs. comparator, including placebo. The rates of EAC
-confirmed 
events of pancreatic cancer were 
consistently low across trials. Subjects with presence or history of malignant 
neoplasm within 5 years prior to the day of 
screening will not be enrolled in this trial. 
Medullary thyroid 
cancer  Thyroid C-cell tumours were seen in 
mouse and rat carcinogenicity studies after daily exposure to semaglutide for 2 years. 
The rodent C
-cell tumours are caused by a 
non-genotoxic, specific GLP-1 receptor  
mediated mechanism to which rodents are 
particularly sensitive. No C -cell tumours 
were observed in monkeys after 52 weeks exposure up to 52
-fold above the clinical 
plasma exposure at 14 mg/day. The GLP-1 receptor is not expressed in the normal human thyroid, and therefore the clinical 
relevance of the findings is considered to 
be low. To mitigate this risk, subjects with a family or 
personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) 
are excluded from clinical tria
ls with 
semaglutide.  
Risk of COVID-19 
infection in relation to trial treatment
 Available data does not suggest an 
increased risk of infection or a more severe progression of infection when treated with oral semaglutide. 
 More detailed information about the known risks 
for oral semaglutide may be found in the 6;C2@A64.A<?N@/?<05B?2
5, Prescribing 
informati on7 or Summary of product 
characteristics.6 CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 16 of 93 
 
Potential risk of 
clinical 
significance  Summary of data/rationale for risk  Mitigation strategy 
Trial treatment (semaglutide) 
Trial procedures 
Risk of COVID-19 
infection in relation to participation in trial
 Subjects may be exposed to the risk of 
COVID -19 transmission and infection in 
relation to site visits if an outbreak is 
ongoing in the given country.  The risk of COVID-19 transmission in relation 
to site visits is overall considered to be low, however this may vary between geographical area. To minimize the risk as much as possible, the following measures have been taken
: 
 Cautious subject recruitment pl anning 
ensures controlled subject enrolment in 
countries where the COVID-19 
pandemic is evaluated to be sufficiently 
under control, and at sites where health 
care resources are evaluated to be 
adequate. 
 The number of physical on- site visits 
has been limite d to the extent possible. 
Phone visits have to the extent possible 
replaced on-site visits. 
 On-site visits will be well- prepared and 
as short as possible. Physical contact between subjects and site staff will be 
limited to the extent possible, and 
protective measures will be implemented. 
 A COVID-
19 mitigation plan has been 
developed for this trial which lists the 
additional actions to consider in case a 
site or country are locked down and subjects cannot attend on-site visits. 
Other 
Pregnancy and 
fertility  Studies in animals have shown 
reproductive toxicity. There are limited 
data from the use of semaglutide in pregnant women.
 Semaglutide should not be used during 
pregnancy. Women of childbearing potential are 
required to use highly effective contraceptive methods when participating in this trial 
(Appendix 4 (
Section 10.4), Table 10-3 ). If a 
subject wishes to become pregnant, or pregnancy 
occurs, semaglutide should be discontinued (please refer to 
Section 8.3.5  for further 
guidance). The effect of semaglutide on fertility 
in humans is unknown.  
2.3.2 Benefit assessment 
Oral semaglutide has demonstrated clinicall y relevant and dose-dependent improvements in 
glycaemic control and body weight reduction in subjects with T2D. Also, the reduction in HbA 1c 
was consistently greater with higher baseline HbA 1c.8 Consequently, it is expected that oral 
semaglutide 25 mg and 50 mg will provide improved glycaemic and body weight control in subjects 
with T2D as compared to semaglutide 14 mg , the current maximum maintenance dose approved. 
All subjects will therefore be treated with a regi men expected to be more efficacious compared to 
the treatment they receive at trial entry. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 17 of 93 
 
In addition, it is expected that all subjects will benefit from participation through close contact with 
the trial site with close monitoring and treatment of T2D and a careful medical examination, all of 
which will most likely result in an intensified management of their diabetes. 
Investigators will ensure that subjects are treated  according to recommended standard-of-care for 
T2D management. Safety and efficacy will be monitored regularly, and acceptable glycaemic 
control will be reinforced at all times during the trial. 
All subjects in this trial will receive trial product and auxiliary supplies free of charge. 
2.3.3 Overall benefit-risk conclusion 
Necessary precautions have been implemented in the design and planned conduct of the trial in 
order to minimise the risks and inconveniences of participation in the trial. The safety profile for 
semaglutide generated from the clinical and non-clinical development programme has not revealed 
any safety issues that would prohibit administration of oral semaglutide doses up to 50 mg once 
daily. The results of the phase 2 trial (NN9924-3 790) indicate a dose-dependent reduction of HbA 1c 
and body weight following treatment with oral semaglutide. 
It is therefore concluded that the potential benefits  from the trial will outweigh the potential risks 
for the subjects. More detailed information about the known and expected benefits and risks and reasonably expected AEs of oral @2:.49BA612:.F/23<B;16;A52 ;C2@A64.A<?N@?<05B?2 
5 and 
any updates hereof. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 18 of 93 
 
3 $&#! $#  
3.1 Primary and secondary objectives, and estimands 
Primary objective To confirm superiority of oral semaglutide 25 mg and 50 mg once 
daily versus oral semaglutide 14 mg once daily on HbA 1c reduction in 
subjects  with T2D on stable dose of 1-3 OADs. 
Secondary objectives To confirm superiority of oral semaglutide 25 mg and 50 mg once 
daily versus oral semaglutide 14 mg once daily on body weight reduction in 
subjects with T2D on a stable dose of 1-3 OADs. 
To compare the efficacy of oral semaglutide 25 mg and 50 mg once 
daily versus oral semaglutide 14 mg once daily on parameters related to glycaemic control in 
subjects with T2D on a stable dose of 1-3 
OADs.  
To compare the efficacy of oral semaglutide 25 mg and 50 mg once 
daily versus oral semaglutide 14 mg once daily on parameters related to weight
-related outcomes in subjects with T2D on a stable dose of 1-
3 OAD s. 
To compare the safety and tolerability of oral semaglutide 25 mg and 
50 mg once daily versus oral semaglutide 14 mg once daily in subjects with T2D on stable dose of 1
-3 OADs. 
Estimands 
For the primary and the confirmatory secondary objective, estimands of primary interest and 
additional estimands are defined. The estimands are used to address the trial objectives in terms of 
two different aspects of the treatment effect of oral semaglutide 14, 25 and 50 mg. Three 
intercurrent events are considered: Premature trial treatment discontinuation (due to any reason), 
change in dose and initiation of additional anti-d iabetic medication. Intercurrent events are events 
occurring after treatment initiation that af fect the interpretation or the existence of the 
measurements associated with the questions of interest.  
The estimands for the primary objective are introduced  below and the attributes of the estimands are 
summarised in Table 3-1 . Additional details are available in Section 9.  
Similar estimands are applied to the objective related to superiority in change in body weight . 
The primary estimand  addresses the main question of interest: What is the efficacy of oral 
semaglutide 25 and 50 mg versus oral semaglutide 14 mg on change from baseline to week 52 in 
HbA 1c in subjects with T2D on stable dose of 1-3 OADs regardless of prematu re trial treatment 
discontinuation, changes in dose and initiati on of additional anti-diabetic medication.  
For this estimand, the treatment policy strategy is applied for all intercurrent events (Section 9.3 and 
Table 9-3) . Data collection will continue after an inte rcurrent event and the collected data will be 
included in analyses regardless of the occurrence of the event. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 19 of 93 
 
Results based on the primary estiman d are expected to mirror the clinical practice scenario because 
the estimand considers both the efficacy and tolerability of oral semaglutide. In addition, a similar 
estimand is represented in the label for RybelsusÂ®. 
The additional estimand  addresses an additional question of interest: What is the efficacy of oral 
semaglutide 25 and 50 mg versus oral semaglutide 14 mg on change from baseline to week 52 in 
HbA 1c in subjects with T2D on stable dose of 1- 3 OADs regardless of change in dose of trial 
treatment and if all subjects had remained on tr ial treatment without use of rescue medication.  
For this estimand, a hypothetical strategy is applied for two of the intercurrent events (premature 
trial treatment discontinuation and initiation of rescue medication). The treatment policy strategy is 
used to handle any changes in trial treatment dose level because this intercurrent event is part of the 
pre-specified treatment regimen.  
The additional estimand is considered relevant becaus e it quantifies the achievable treatment effect 
without potentially confounding effects of any rescue medication. Further, results obtained with the 
additional estimand allows for comparison with results from the oral semaglutide phase 3a 
programme (PIONEER), which applie d a similar additional estimand.  CONFIDENTIAL
Protocol       Date: 16 September 2022 Status:  Final  Novo Nordisk 
Trial ID: NN9924-4635       Version: 7.0 Page: 20 of 93 
 
Table 3-1 Estimands 
Objective Estimand 
category Attributes 
Treatment condition Variable / 
endpoint  Population of 
interest  Intercurrent events and 
strategy  Population-
level summary 
measure  
Primary objective: 
To confirm superiority of oral semaglutide 
25 mg and 50 mg once daily versus oral semaglutide 14 mg once daily on HbA
1c 
reduction in subjects with T2D on stable 
dose of 1 -3 OADs Primary  
 The effect of high doses of oral semaglutide with 
or without additional anti-diabetic medication 
versus the effect of oral sema glutide 14 mg with or 
without additional anti-diabetic medication, both 
as add -on to stable dose of 1-3 OADs Change in 
HbA 1c from 
baseline to week 
52 T2D subjects as 
defined by the protocol inclusion and exclusion criteria Treatment policy  
strategy for:  
 Premature trial 
treatment discontinuation 

 Dose change 
 Initiation of 
additional anti-
diabetic medication Difference in 
means  
Additional*  The effect of high doses of oral semaglutide 
without rescue medication versus the effect of oral 
sema glutide 14 mg without rescue medication, 
both as add -on to stable dose of 1-3 OADs Hypothetical strategy 
for: 
 Premature trial 
treatment discontinuation  

 Initiation of rescue 
medication  
Treatment policy  
strategy for:  
 Dose change 
Protocol       Date: 16 September 2022 Status:  Final  Novo Nordisk 
Trial ID: NN9924-4635       Version: 7.0 Page: 21 of 93 
 
Objective Estimand 
category Attributes 
Treatment condition Variable / 
endpoint  Population of 
interest  Intercurrent events and 
strategy  Population-
level summary 
measure  
Secondary objective: 
To confirm superiority of oral semaglutide 
25 mg and 50 mg once daily versus oral 
semaglutide 14 mg once daily on body 
weight reduction in subjects with T2D on 
stable dose of 1-3 OADs Secondary  The effect of high doses of oral semaglutide with 
or without additional anti-diabetic medication 
versus the effect of oral semaglutide 14 mg with or 
without additional anti-diabetic medication, both 
as add -on to stable dose of 1-3 OADs Change in body 
weight from 
baseline to 
week 52 T2D subjects as 
defined by the 
protocol inclusion 
and exclusion criteria Treatment policy 
strategy for: 
 Premature trial 
treatment discontinuation 

 Dose change 
 Initiation of 
additional anti-diabetic medic
ation Difference in means
 
Additional*  The effect of high doses of oral semaglutide without 
rescue medication versus the effect of oral 
sema glutide 14 mg without rescue medication, 
both as add -on to stable dose of 1-3 OADs Hypothetical strategy 
for: 
 Premature trial 
treatment discontinuation 

 Initiation of rescue 
medication 
Treatment policy  
strategy for:  
 Dose change 
* Not related to the confirmatory hypotheses  
Similar estimands are defined for the other efficacy objectives.
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 22 of 93 
 
3.2 Primary and secondary endpoints 
3.2.1 Primary endpoint 
Endpoint title Timeframe Unit 
Change in glycated haemoglobin (HbA 1c) From baseline (week 0) to week 52 %-point 
3.2.2 Secondary endpoints 
3.2.2.1  Confirmatory secondary endpoints 
3.2.2.2  Supportive secondary endpoints 
Endpoint title Timeframe Unit 
Change in fasting plasma glucose (FPG) From baseline (week 0) to week 52 mmol/l 
Achievement of HbA 1c <7% (Yes/No)  At week 52 Count of subjects 
Achievement of HbA 1c H-2@	%<  At week 52 Count of subjects 
Relative change in body weight  From baseline (week 0) to week 52 Percentage (%) 
Change in waist circumference From baseline (week 0) to week 52 cm 
0562C2:2;A<3D2645A9<@@I-2@	%<  At week 52 Count of subjects 
0562C2:2;A<3D2645A9<@@I
-2@	%<  At week 52 Count of subjects 
Adverse events From baseline (week 0) to follow-up visit 
(week 73) Count of events Endpoint title Timeframe Unit 
Change in body weight  From baseline (week 0) to week 52 kg CONFIDENTIAL
Protocol
CONFIDENTIALDate: 16 September 2022 Novo Nordisk
Trial ID: NN9924-4635 Version: 7.0
     Status: Final
     Page: 23 of 93
4"#
4.1 Overall design
This is a 68-week, randomised, active-contro lled, double-blinded, three-armed, multi-centre, 
multinational clinical trial. 
Eligible subjects will be randomised in a 1:1:1 manner to receive either: 
oral semaglutide 50 mg once daily
oral semaglutide 25 mg once daily
oral semaglutide 14 mg once daily
Randomisation will be stratified by baseline an ti-diabetic medication: Â± SU, Â±SGLT2 inhibitor, 
Â±terminated DPP-4 inhibitor. Consequently, randomisa tion will comprise 8 strata for combinations 
of SU, SGLT2 inhibitor, and terminated DPP-4 in hibitor. Metformin is not included in the 
stratification. A 30% cap on DPP-4 inhibitor users will be implemented to equalise the 
representation of baseline background anti-diabetic medication across the population.
The trial comprises a 2- D228@0?22;6;4=2?6<1A<.@@2@@A52@B/720AN@29646/696AF3<99< D21/F.
randomisation visit (V2) and a 68-week treatment period. The treatment period is divided into a 
dose escalation period of 8-16 weeks and a mainte nance period of 52-60 weeks. After the end-of-
treatment visit (V16), all subjects will enter a follow-up period of 5 weeks, ended by a follow-up 
visit (V17), which corresponds to the end of th e trial. The planned total trial duration for the 
individual subject is approximately 75 weeks (including screening).
The trial design is illustrated in Figure 4-1
Figure 4-1 Trial design
4.2 Scientific rationale for trial design
The trial has been designed as an active-control led, double-blinded, parallel , three-armed trial to 
ensure a direct comparison of oral semaglutide 25 mg, 50 mg, and 14 mg.
A randomised, double-blind trial design was chosen to minimise bias in the assessment of the 
efficacy and safety of oral semaglutide 25 and 50 mg. The formulation (shape and composition) of 
the tablets, used for the 25 mg and 50 mg dose levels, has been updated to improve bioavailability 
CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 24 of 93 
 
as compared to the formulation of the tablets used for the 14 mg dose level. Consequently, the 
shape of the tablets will have a minor difference a nd will not be visually identical. However, the 
double-blind design is considered justified because:  1) identical primary and secondary packaging is 
used for all tablets in all treatment arms; 2) a thir d-party, who is only allowed to be involved in trial 
product handling will be responsible for drug accountability (see Section 6.3). Of note, a double-
dummy design was not considered feasible considering the dosing conditions for oral semaglutide.  
The planned treatment duration of the trial is 68 weeks, with an additional 5 weeks of follow-up to 
account for the exposure and long half-life of sema glutide. An evaluation of the efficacy-related 
parameters after a 52-week treatment period is cons idered appropriate and in line with regulatory 
guidance and with previous trials in T2D, including the PIONEER phase 3a trials. A total treatment 
duration of 68 weeks will ensure a robust safety and tolerability evaluation. 
Predictions based on PIONEER and SUSTAIN exposure -response modelling indicate stabilisation 
or minimal increase in the effect of semaglutide on HbA 1c beyond 26 weeks of treatment. The 
exposure-response models indicate, however, additional weight benefit at week 52 compared to 
week 26 based on approximately 30 weeks on main tenance dose. The primary and confirmatory 
secondary endpoints are therefore de fined after 52 weeks of treatment. 
Evaluation of the 20-40% of subjects failing to reach the glycaemic target of HbA 1c <7% after 26 
weeks on oral semaglutide 14 mg in the PIONEER phase 3a programme suggests that the 
population likely to particularly benefit from a dose of oral semaglutide higher than 14 mg is 
characterised by high baseline HbA 1c (>8%) and high baseline BMI (>25 kg/m2). Such patients with 
T2D in need of treatment intensification are very likely to receive a broader range of anti-diabetic 
medication at baseline; therefore, treatment with stable dose of 1-3 oral anti-diabetic drugs (OADs) 
at baseline is allowed (see Section 5.1).  
This population is considered to be clinically relevant, because it is likely to benefit both from the 
better glycaemic control and the additional body weight loss anticipated to be achievable with the 
higher doses of oral semaglutide. 
4.3 Justification for dose 
The oral semaglutide doses of 25 mg and 50 mg are chosen to ensure that the increments between 
the doses provide clinically meaningful differentiat ion between their effects on glycaemic control 
while displaying a satisfactory safety and tolerability profile.  
Relative to formulation used for the currently approved doses of RybelsusÂ®, the formulation for oral 
semaglutide 25 mg and 50 mg has been changed with  regards to excipient composition. This change 
in formulation is based on results from tria l NN9924-4427, as it is anticipated that the new 
formulation will lead to improved bioavailability relative to the formulation for the currently 
approved doses of RybelsusÂ®. In trial NN9924-4427, exposure of healthy male subjects to once 
daily dosing of the new formulation of oral semaglutide (5 days on 3 mg and 5 days on 7 mg) 
resulted in an increase in semaglutide exposure by approximately 25% compared to the formulation 
of the currently marketed doses of oral semaglutide (RybelsusÂ®). 
Using pharmacokinetic (PK) simulations and assuming dose-proportionality, 25 mg and 50 mg 
semaglutide are expected to result in C avg of 36.5 (90% range:11.4-92.3) nmol/L and 72.9 (90% CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 25 of 93 
 
range:22.8-184.7) nmol/L, respectively. The simulated oral semaglutide concentrations are based on 
a population PK model developed on a trial population matching subjects on 14 mg oral 
semaglutide from PIONEER 1, 2, 8 and 9 (trials NN9924-4233, 4223, 4280 and 4281).  
An exposure level higher than the one potentially reached with steady-state treatment of 25 mg oral 
semaglutide has already been tested in previous trials with oral and s.c. semaglutide. In the oral 
semaglutide phase 2 trial (NN9924-3790), subjects with T2D received up to 40 mg oral 
semaglutide. In this trial, the highest C avg observed in the highest dose arm (40 mg) was 
185 nmol/L.  
The semaglutide exposure level potentially reache d with steady-state treatment of 50 mg oral 
semaglutide (C avg of 72.9 [90% range: 22.8-184.7] nmol/L) are similar to or may be higher than 
dose levels previously tested. Approximately 5% of subjects on 50 mg are likely to achieve an 
exposure level above the maximum exposure level observed with oral semaglutide in trial NN9924-
3790 (highest C avg observed was 185 nmol/L) where subjects were treated with doses up to 40 mg. 
In addition, s.c. semaglutide 0.3 mg and 0.4 mg once daily (corresponding to a weekly dose of 2.1 
mg and 2.8 mg, respectively) have been dosed to subjects with T2D or obesity in trials NN9535-
4191 and NN9536-4153, respectively. In the obese population, the highest observed C avg for s.c. 
semaglutide 0.4 mg was 128 nmol/L (trial 4153). No une xpected safety or tolerability findings were 
observed in either of the trials. 
Based on prior experience with oral semaglutide (NN9924-3790 and the PIONEER programme) 
and other GLP-1 RAs, low starting dose and gradual dose escalation of oral semaglutide is expected 
to mitigate the risk of developing GI sympto ms. To increase GI tolerability, possible dose 
reductions and extensions of dose-escalation periods will be introduced based on clinical evaluation 
made by the investigator (see Section 6.6). 
4.4 End of trial definition 
A subject is considered to have completed the tria l if he/she has completed all phases of the trial, 
including the follow-up visit (V17). 
The end of the trial is defined as the date of the last visit of the last subject in the trial globally. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 26 of 93 
 
5 "! !%$   
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1 Inclusion criteria 
Subjects are eligible to be included in the trial only if all of the following criteria apply: 
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial. 
2. Male or female, age above or equal to 18 year s at the time of signing informed consent. 
3. 6.4;<@21D6A5AF=216./2A2@:2996AB@I
1.F@=?6<?A<A52 1.F<3@0?22;6;4  
4. HbA 1c of 8.0- 
P: mol/mol) (both inclusive). 
5. $ I 5.0 kg/m2. 
6. Stable daily dose(s) for 90 days prior to the day of screening of: any of the following treatment 
regimens: 
- No more than 3 of the following oral anti-diabetic drugs and at least 1 marked with a *: 
o * $2A3<?:6;I 1500 mg or maximum tolerated or effective dose). 
o * (B93<;F9B?2.@(*I5.93<3A52:.E6:B:.==?<C211<@2.00<?16; 4A<9<0.99./29
or maximum tolerated or effective dose). 
o * SGLT2 inhibitors (maximum tolerated dose). 
o DPP-4 inhibitors (maximally indicated dose as per local label). 
7. Subjects, on treatment with stable dose of DPP-4 i nhibitors at inclusion, must be willing to 
terminate DPP-4 inhibitor treatment at randomisation (with no wash-out). 
Taiwan: for country-specific requirements, please see Appendix 8 (Section 10.8). 
5.2 Exclusion criteria  
Subjects are excluded from the trial if any of the following criteria apply: 
1. Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria within the past 90 days prior to the day of screening. However, short-term 
insulin treatment for a maximum of 14 days prior to the day of screening is allowed. 
2. Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) 
known to affect body weight or glucose metabolism (e.g. treatment with orlistat, thyroid 
hormones, or systemic corticosteroids). 
3. Renal impairment measured as estimated glom erular filtration rate (eGFR) value of 
<30 mL/min/1.73 m2 according to CKD-EPI creatinine equation as defined by KDIGO 2012 
classification. 
4. Uncontrolled and potentially unstable diabetic re tinopathy or maculopathy. Verified by a fundus 
examination performed within the past 90 days prior to screening or in the period between 
screening and randomisation. Pharmacological pu pil-dilation is a requirement unless using a 
digital fundus photography camera specified for non-dilated examination. 
5. History of major surgical procedures involving the stomach potentially affecting absorption of 
drugs and/or nutrients, as judged by the investigator. 
6. Personal or first-degree relative(s) history of mult iple endocrine neoplasia  type 2 or medullary 
thyroid carcinoma. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 27 of 93 
 
7. Presence or history of pancreatitis (acute or chronic). 
8. Myocardial infarction, stroke, hospitalization for uns table angina pectoris or transient ischaemic 
attack within 180 days prior to the day of screening. 
9. Presently classified as being in New York Heart Association (NYHA) Class IV. 
10. Planned coronary, carotid or peripheral artery revascularisation. 
11. Presence or history of malignant neoplasm within 5 years prior to the day of screening. Basal 
and squamous cell skin cancer and any carcinoma in-situ is allowed. 
12. Known or suspected hypersensitivity to trial products or related products. 
13. Previous participation in this trial. Participation is defined as signed informed consent. 
14. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using a highly effective contraceptive method. 
15. Participation in any clinical trial of an approv ed or non-approved investigational medicinal 
product within 3 months before screening*. 
16. Other subject(s) from the same household participating in any oral semaglutide trial 
17. ;F16@<?12?B;D6996;4;2@@<?6;./696AFD56056;A526;C2@A64 .A<?N@<=6;6<;:645A72<=.?16@2
@B/720AN@@.32AF<?0<:=96.;02D6A5A52=?<A<0<9  
*Simultaneous participation in a trial with the primary objective of evaluating an approved or 
non-approved investigational medicinal product for prevention or treatment of COVID-19 disease 
or COVID-19 postinfectious conditions is allowed if the last dose of the investigational medicinal 
product has been received more than 30 days before screening. 
Croatia and Germany: for country-specific re quirements, please see Appendix 8 (Section 10.8). 
5.3 Lifestyle considerations 
To ensure alignment regarding performance of assessments across subjects and trial sites, the below 
restrictions apply. 
5.3.1 Meals and dietary restrictions 
The trial product must: 
 be taken on an empty stomach in the morning at  least 30 minutes before intake of food, liquids 
or other oral medicinal products. 
 waiting less than 30 minutes, or taking with food,  beverages (other than water) or other oral 
medication will lessen the ef fect of oral semaglutide. 
 waiting more than 30 minutes might increase the absorption of oral semaglutide. 
 be taken with no more than a half a glass of water equivalent to 120 ml (4 ounces). 
 be swallowed whole. 
 not be split, crushed or chewed. 
Subjects must attend visits fasting according to the flowchart (Section 1.2). Fasting is defined as: 
 no food or liquid, except for water, for at least 6 hours prior to the visit. 
 no water 2 hours prior to the visit. 
Trial product and any medication which should be taken with or after a meal should be withheld on 
the day of the visit until blood samples have been obtained. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 28 of 93 
 
If the subject is not fasting as required, the subject must be called in for a new visit within the visit 
window to have the fasting procedures performed. 
5.4 Screen failures 
Screen failures are defined as subjects who consen t to participate in the clinical trial but are not 
eligible for participation according to inclusion/ex clusion criteria. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure subjects to meet 
requirements from regulatory authorities. Minimal information includes informed consent date, 
demography, screen failure details, eligibility cr iteria, completion of end-of-trial form and any 
serious adverse event (SAE). 
A screen failure session must be made in the interactive web response system (IWRS). 
Individuals who do not meet the criteria for participation in this trial may not be rescreened. If the 
subject has failed one of the inclusion criteria or fulfilled one of the exclusion criteria related to 
laboratory parameters, re-sampling is not allowed. However, in case of technical issues (e.g. 
haemolysed or lost), re-sampling is allowed for the affected parameters. 
5.5 Run-in criteria and randomisation criteria and dosing day criteria 
Not applicable for this trial. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 29 of 93 
 
6 "$$#  
6.1 Treatments administered 
Investigational medicinal products  
The investigational medicinal products (IMP, trial products) provided by Novo Nordisk are listed in 
Table 6-1.  
Table 6-1 Investigational medicinal products provided by Novo Nordisk 
Description Trial product (IMP) 
name Dosage form Route of 
administration Dosing instruction Packaging 1 
Semaglutide Semaglutide 3 mg Tablet Oral 1 tablet in the morning as 
described in Section 5.3.1  Dose pack 
Semaglutide Semaglutide 7 mg Tablet Oral 1 tablet in the morning as 
described in Section 5.3.1  Dose pack 
Semaglutide Semaglutide 14 mg Tablet Oral 1 tablet in the morning as 
described in Section 5.3.1  Dose pack 
HDPE bottle  
Semaglutide Semaglutide C 25 mg Tablet Oral 1 tablet in the morning as 
described in Section 5.3.1  HDPE bottle 
Semaglutide Semaglutide C 50 mg Tablet Oral 1 tablet in the morning as 
described in Section 5.3.1  HDPE bottle  
1: A dose pack contains one blister card with 7 tablets. A high density polyurethane (HDPE) bottle contains 30 tablets. 
Directions for use  
The investigator must document that directions for use (DFU) are given to the subject orally at the 
first dispensing visit (as specified in the flowchart in Section 1.2). The investigator should remind 
subjects of dosing instructions (as described in Section 5.3.1 ) ongoing throughout the trial, as 
applicable. 
Participants must be instructed to take oral semaglutide at least 30 min before the first food, 
beverage or other oral medications of the day with  no more than 120 mL or 4 ounces of plain water. 
Waiting less than 30 minutes, or taking food, beve rages (other than plain water) or other oral 
medications will lessen the effect of oral semaglut ide. Waiting more than 30 minutes to eat may 
increase the absorption of oral semaglutide. The tablet must be swallowed whole. The tablet must 
not be cut, crushed or chewed.  
Dose escalation 
Dose escalation of oral semaglutide should ta ke place during the first 8-16 weeks after 
randomisation as illustrated in Table 6-2 . All subjects should aim at reaching the randomised target 
dose of oral semaglutide once daily. 
 
 CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 30 of 93 
 
Table 6-2 Treatment overview 
  Dose escalation/maintenance Maintenance  Follow-up  
Trial periods  Screening  Randomisation/ 
Treatment-
period 1 Treatment- 
period 2  Treatment- 
period 3  Treatment- 
period 4  Treatment- period 5 End of treatment  
Duration of each 
period 2 weeks 4 weeks 4 weeks 4 weeks 4 weeks 52 weeks 5 weeks 
Treatment arm  
Oral semaglutide  
50 mg Screening Oral  
semaglutide 
3 mg 
Dose pack  Oral 
semaglutide 
7 mg 
Dose pack Oral 
semaglutide 
14 mg  
Dose pack Oral 
semaglutide 
25 mg  
HDPE bottle Oral semaglutide 
50 mg 
HDPE bottle  Follow-up 
Oral semaglutide  
25 mg Screening Oral  
semaglutide  
3 mg  
Dose pack  Oral 
semaglutide 
7 mg 
Dose pack Oral 
semaglutide 
14 mg  
Dose pack Oral 
semaglutide 
25 mg  
HDPE bottle Oral semaglutide 
25 mg 
HDPE bottle  Follow-up 
Oral semaglutide  
14 mg Screening Oral  
semaglutide  
3 mg 
Dose pack  Oral 
semaglutide 
7 mg 
Dose pack Oral 
semaglutide 
14 mg  
Dose pack Oral 
semaglutide 
14 mg  
HDPE bottle Oral semaglutide 
14 mg 
HDPE bottle  Follow-up 
HDPE = High density polyurethane. 
Missed doses 
If a dose is missed, the missed dose should be skipped, and the next dose should be taken the 
following day.  
If consecutive doses of trial treatment are missed, th e subject should be encouraged to re-commence 
A52A?2.A:2;A630<;@612?21@.32.@=2?A526;C2@A64.A<?N@16@0 ?2A6<;.;163A52@B/720A1<2@;<A:22A
any of the discontinuation criteria (Section 7.1). The trial treatment should be continued as early as 
the situation allows. If the subject has been off treatment for more than 10 consecutive days, the 
investigator should consult Novo Nordisk global medical experts for guidance regarding 
continuation of trial medication. 
Auxiliary supplies 
The following auxiliary supplies will be provided by Novo Nordisk: 
 Blood glucose (BG) meter and related auxiliaries 
Subjects will be instructed in how and when to use the BG meter and the instructions will be 
repeated during the trial as needed. 
Shipment of trial product to #%$)#  home 
For selected countries and if permitted by local regulations, the investigator may offer to send trial 
product and auxiliaries from the trial site or pharmacy to the @B/720AN@ home by courier service. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 31 of 93 
 
The process for sending trial product from  the trial site or pharmacy to a @B/720AN@  home is 
12@0?6/216;A52K)? 6.9@6A2	=5.?:.0F6;@A?B0A6<;3<?@56=:2;A <3A?6.9=?<1B0AA<=.A62;A@N5<:2@L
document. This document contains detailed instruc tions for preparing packaging and setting up the 
pick-up of trial product, handover of trial product from  the trial site or pharmacy staff to the courier, 
required temperature monitoring of trial product, de livery to and receipt of trial product by the 
subject. The process for returning trial product to the trial site or pharmacy by courier is also 
described in this document. 
Investigators, trial site/pharmacy staff and subjects who will be involved in shipment of trial 
product to the @B/720AN@  home will be adequately trained in this process. 
Please note that the drug dispensing and accountabil ity are handled by the third-party, as described 
in Section 4.2 and 6.3. 
6.2 Preparation/handling/storage/accountability 
Only subjects randomised to treatment may use trial product and only delegated site staff may 
supply trial product. 
 Each site will be supplied with sufficient tria l products for the trial on an ongoing basis. Trial 
products will be distributed to the sites according to screening and randomisation. 
 The investigator or designee must confirm that  appropriate temperature conditions have been 
maintained during transit for all trial products received, and that any discrepancies are reported 
and resolved before use of the trial products. 
 All trial products must be stored in a secure, controlled, and monitore d (manual or automated) 
area in accordance with the labelled storage conditions with access limited to the investigator and delegated site staff. 
 The investigator must inform Novo Nordisk immediately if any trial product has been stored 
outside specified conditions. The trial product must not be dispensed to any subject before it has 
been evaluated and approved for further use by Novo Nordisk. Additional details regarding 
handling of temperature deviations can be found in the trial materials manual (TMM). 
 The investigator or designee is responsible for dr ug accountability and record maintenance (i.e. 
receipt, accountability and final disposition records). 
 The investigator or designee must instruct the subject in what to return at next visit. 
 Drug accountability must be performed in the IWRS  by registering tablets as returned either un-
used or as lost. 
 Destruction of trial products can be performed on an ongoing basis and will be done according 
to local procedures after accountability is finalised by the site.  Destruction of trial product must be documented in the IWRS. 
 All returned, un-used, expired or damaged trial products (for tec hnical complaint samples, see 
Section 10.5) must be stored separately from non-allocated trial products. No temperature 
monitoring is required. 
 Non-allocated trial products including expired or damaged products must be accounted as 
unused, at the latest at closure of the site. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 32 of 93 
 
6.3 Measures to minimise bias: Randomisation and blinding 
All subjects will be centrally screened and randomised using an IWRS and assigned to the next 
available treatment according to randomisation schedu le. Trial treatment will be dispensed/allocated 
at the trial visits summarised in the flowchart (Section 1.2). 
Subjects will be randomly assigned in a 1:1:1 ratio to receive trial treatment. 
At screening, each subject will be assigned a unique 6-digit subject number which will remain the 
same throughout the trial. Each site is assigned a 3-digit number and all subject numbers will start 
with the site number. 
Dose reduction to lower doses than 14 mg is not allowed (see Section 6.6). Consequently, the 
allowed dose reduction steps will not induce chan ge of trial product packaging and therefore not 
compromise the double-blinded trial design. 
Investigators and site personnel are to remain blinded throughout the trial. Due to the minor 
differences in tablet shapes, the primary and second ary packaging are identical in all treatment arms 
to maintain the blinding (see Section 4.2). Further, a third-party will be responsible for drug 
accountability of all trial products and an unblinde d monitor will be responsible for drug 
reconciliation (see Section 10.1.8.2 ). It will not be possible for the third-party or the unblinded 
monitor to see the actual treatment. The third-pa rty will also be allowed to handle trial product 
arrival and temperature monitoring of trial product including handling of potential temperature 
deviations. The unblinded monitor will also be allowed to check documentation regarding potential 
temperature deviations. The unblinded monitor will also be allowed to check documentation 
regarding above tasks and be involved in trial product destruction according to local procedures. 
It is recommended that the third-party also is re sponsible for dispensing of all trial products, but in 
case site personnel and/or investigator needs to be  responsible for dispensing of trial products, they 
are only allowed to handle trial product in its original packaging material (unbroken packaging). 
The third-party and the unblinded monitor will not be involved in any other trial procedures. 
The IWRS is used for blind-breaking. In case of an emergency, the investigator has the sole 
responsibility for determining if unblinding of .@B/720A@NA?2.A:2;A6@D.??.;A21(B/720A@.32AF
must always be the first consideration in making such a determination. 
If the investigator decides that unblinding is warranted, the investigator should make every effort to 
contact Novo Nordisk prior to u ;/96;16;4.@B/720A@NA?2.A:2;AB;92@@A56@0<B91129.F2:2?42; 0F
A?2.A:2;A<3A52@B/720A 3.@ B/720AN@A?2.A:2;A6@B;/96;121 %<C<%<?16@89</.9(.32AF
department) must be notified within 24 hours afte r breaking the blind. The date and reason that the 
blind was broken must be recorded in the source documentation.  
The person breaking the blind must print the "code  break confirmation" notification generated by 
the IWRS, sign and date the document. If IWRS is not accessible at the time of blind break, the 
IWRS helpdesk should be contacted. Contact details are listed in Attachment I . Subject will 
continue on trial treatment after blind break. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 33 of 93 
 
6.4 Treatment compliance 
Drug treatment compliance 
Throughout the trial, the investigator will remi nd the subjects to follow the trial procedures and 
requirements to encourage subject compliance. Compliance is defined as taking between 
80%-120% of the dose as prescribed between visits.  
When subjects self-administer trial treatment at ho me, compliance with trial treatment will be 
assessed and the assessment documented in source doc uments at each visit where information is 
available. If any suspicion of non-compliance arises, the site must enter into a dialogue with the 
subject, re-emphasizing the importance of complian ce and uncover barriers to compliance. This 
dialogue must be documented. Compliance will be assessed by cross checking the following 
sources and comparing these to the expected use:  
 Drug accountability information; counting returned trial product 
 Questioning of subjects about missed doses 
Treatment start and stop dates will be recorde d in the electronic case report form (eCRF). 
6.5 Concomitant medication 
Any medication (including over-the-counter (OTC) or  prescription medicines) other than the trial 
treatment that the subject is receiving at the time of  the first visit or receives during the trial must be 
recorded along with: 
 Trade name or generic name 
 Indication 
 Dates of administration including start and stop dates 
 Dose (only to be recorded for anti-hyperglycaemic medication and levothyroxine) 
 Time of dosing (only to be recorded for levothyroxine) 
 Medication administered in relation to a clinical trial for COVID-19 prevention or treatment 
 Approved COVID-19 vaccine 
After signing the informed consent, subjects mu st continue their OADs (with the exception of 
DPP-4 inhibitors J see Section 4.1 and 5.1) at the same dose level and with the same dosing 
frequency throughout the entire treatment period unless safety concerns related to the use their 
OADs arise.  
To mitigate SU-induced hypoglycaemia, subjects trea ted with SU should, at the discretion of the 
investigator, reduce the SU dose at randomisation by approximately 50%. 
Apart from the initial dose reduction of SU, background medication dose should remain at the same 
dose level and with the same frequency during the entire treatment period unless glycaemic rescue 
treatment is needed (as described in Section 7.1.2 ) or safety concern related to the use of 
background medications arises. 
Investigators can switch OAD treatment within the same drug class, e.g. in case specific drugs 
become unavailable. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 34 of 93 
 
Changes in concomitant medication, including switch  of OAD treatment within the same drug class, 
must be recorded at each visit.  If a change is due to an AE,  then this must be reported according to 
Section 8.3. 
Croatia and Germany: for country-specific requirements, please see Appendix 8 (Section 10.8). 
6.5.1 Rescue medication 
Glycaemic rescue medication, i.e. intensification of  background OAD treatment and/or initiation of 
new anti-hyperglycaemic treatment, should be imple mented at the discretion of the investigator in 
case of persistent hyperglycaemia. Please see Section 7.1.2 . 
Rescue medication should be selected acc ording to American Diabetes Association 
(ADA)/European Association for the Study of Diabetes (EASD) guideline4 (excluding GLP-1 RAs, 
DPP-4 inhibitors and amylin analogues).  
Subjects that are started on rescue medication should  continue to follow the protocol-specified visit 
schedule and stay on randomised treatment unless the investigator judge that it jeopardises s B/720AN@
safety. 
Rescue medication should be doc umented in medical records and reported on the concomitant 
medication form in the electronic case report form (eCRF). 
Rescue medication will not be supplied by Novo Nordisk. 
6.6 Dose modification 
Subjects should be dose escalated as indicated in Table 6-2  and Figure 4-1 . However, if treatment 
with oral semaglutide 25 mg and 50 mg are asso ciated with unacceptable GI AEs (moderate to 
severe), dose reduction or extension of dose escalati on intervals are allowed in treatment period 4 
and 5 (see Table 6-2 ) if the GI AEs are causally related to the trial treatment as judged by the 
investigator. This is to accommodate subject tolerabil ity and safety. In these specific, expected rare 
cases dose adjustments are at the discretion of the investigator. It is recommended that the subject 
makes at least one attempt to re-esc alate to the recommended target dose. 
Dose reduction to lower doses than 14 mg is not allowed.  
It is mandatory that the investigator consults Novo Nordisk in case of persistent deviations from the 
planned escalation regimen. 
6.7 Treatment after end of trial 
When discontinuing trial treatment, the subject should be transferred to a suitable marketed product 
at the discretion of the investigator . 
Considering the long half-life of semaglutide and to avoid over-exposure to GLP-1 RAs and 
interference with safety data collection, initiating  GLP-1 RA or DPP-4 inhibitor should be avoided 
between the end-of-treatment visit (V16) and the follow-up visit (V17). CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 35 of 93 
 
7 # $%$  $"$"$$#%$  
# $%$ '$"'  
Treatment of a subject may be discontinued at an y time during the trial at the discretion of the 
investigator for safety, behavioural, compliance or administrative reasons. 
Efforts must be made to have subjects attend and complete all scheduled visit procedures. Only 
subjects who withdraw consent will be considered as withdrawn from the trial. Subjects must be 
educated about the continued scientific importance of their data, even if they discontinue trial 
treatment. 
7.1 Discontinuation of trial treatment 
Discontinuation of treatment can be decided by both the investigator and the subject. 
Subjects who discontinue trial tr eatment should continue with the scheduled visits and assessments 
to ensure continued counse lling and data collection. 
The trial treatment must be discontinued, if an y of the following applies for the subject: 
1. Safety concern as judged by the investigator 
2. Confirmation of acute pancreatitis 
3. Pregnancy 
4. Intention of becoming pregnant 
5. Simultaneous use of an approved or non-approved  investigational medicinal product in another 
clinical trial* 
*Simultaneous participation in a trial with the primary objective of evaluating an approved or 
non-approved investigational medicinal product for prevention or treatment of COVID-19 disease 
or COVID-19 postinfectious conditions is allowed at the investigator discretion without 
discontinuing trial product. 
The subjects should continue with the remaining sc heduled visits and assessments until the time of 
the originally scheduled end-of-treatment  visit (V16) and follow-up visit (V17). 
All efforts should be made to have the subject attend at least visit V10, V14, the end-of-treatment 
visit (V16) and the follow-up visit (V17). If the s ubject does not wish to attend the scheduled clinic 
visits, efforts should be made to have the remaining visits converted to phone contacts. If a subject 
is unwilling to attend any of the remaining visits, information about the attempts to follow up with 
A52@B/720A:B@A/21<0B:2;A216;A52@B/720AN@:2160.9?20<?1  
The primary reason for discontinuation of trial treatm ent must be specified in the end-of-treatment 
form in the eCRF, and final drug accountability must be performed. A tr eatment discontinuation 
session must be made in the IWRS. 
Croatia and Germany: for country-specific re quirements, please see Appendix 8 (Section 10.8). CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 36 of 93 
 
7.1.1 Temporary discontinuation of trial treatment 
If a subject has discontinued trial treatment due to temporary safety concern not related to trial 
product and treatment with trial product is allowed to be resumed, the guide for missed doses 
(Section 6.1) should be followed. In such cases a tr eatment discontinuation session should not be 
made in the IWRS. 
In case of suspicion of acute pancreatitis, the trial treatment should promptly be interrupted 
(treatment discontinuation session should not be made in IWRS before diagnosis of acute 
pancreatitis is confirmed). Appr opriate actions should be initiated, including local measurement of 
amylase and lipase (see Appendix 3 (Section 10.3) for reporting). 
If acute pancreatitis is confirmed, treatment with trial product should not be restarted, and a 
treatment discontinuation se ssion should be made in IWRS. If the Atlanta criteria9 are not fulfilled 
and thus, the suspicion of acute pancreatitis is not confirmed, treatment with trial product may be 
resumed. 
7.1.2 Rescue criteria 
Subjects with persistent and unacceptable hyperglycaemia should be offered treatment 
intensification. To allow time for dose escalation to  maximum dose and to observe the expected 
effect of treatment on glycaemic parameters, rescue criteria will be applied at week 26 and onwards. 
If the HbA 1c exceeds the value described below, and no unexpected discrepancies are found in the 
trend of the subjects previous HbA 1c values, then the subject should be offered treatment 
intensification (rescue medication) at the discretion  of the investigator and in accordance with the 
ADA/EASD guidelines10 (excluding GLP-1 RAs, DPP-4 inhibitors and amylin analogues). 
Rescue medication should be offered from  week 26 (V10) to week 68 (V16) to: 
 subjects with persistent poor glycaemic control, as expressed by a stable HbA 1c value above 
::<9	:<9.;10<;@612?21B;.002=A./9F5645.00<?16;4A <6;C2@A64.A<?N@
assessment. 
Refer to Section 6.5.1  for description of rescue medication. 
7.2 Subject discontinuation/withdrawal from the trial 
A subject may withdraw consent at any time at his/her own request. 
If a subject withdraws consent, the investigator must  make every effort to collect AEs from last visit 
to withdrawal.  
Final drug accountability must be performed even if the subject is not able to come to the site. A 
treatment discontinuation session must be made in the IWRS. 
If the subject withdraws consent, Novo Nordisk ma y retain and continue to use any data collected 
before such a withdrawal of consent. 
If a subject withdraws from the trial, he/she ma y request destruction of any samples taken and not 
tested, and the investigator must document this in the medical record. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 37 of 93 
 
Although a subject is not obliged to give his/her reason(s) for withdrawing, the investigator must 
make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where 
the reasons are obtained, the primary reason for wit hdrawal must be specified in the end of trial 
form in the CRF. 
7.2.1 Replacement of subjects 
Subjects who discontinue trial treatment or wi thdraw from trial will not be replaced.  
7.3 Lost to follow-up 
A subject will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the site. 
The following actions must be taken if a subject fails to return to the site for a required visit: 
 The site must attempt to contact the subject a nd reschedule the missed visit as soon as possible 
and counsel the subject on the importance of maintaining the assigned visit schedule and 
ascertain whether or not the subject wishes to and/or should continue in the trial. 
 Before a subject is deemed lost to follow-up, the investigator or designee must make every 
effort to regain contact with the subject (where  possible, at least three telephone calls and, if 
necessary, a certified letter to the subject's last known mailing address or local equivalent 
methods). These contact attempts should be documented in the subject's source document. 
 Should the subject continue to be unreachable, he /she will be considered to have withdrawn 
from the trial with a primary reason of `lost to follow-up'. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 38 of 93 
 
8 "####$#!" %"#  
 The following sections describe the assessments and procedures, while their timing is 
summarised in the flowchart (Section 1.2) and in Appendix 2 (Section 10.2). 
 Informed consent must be obtained before any trial related activity, see Section 10.1.3 . 
 All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all inclusion criteria and none of the exclusion criteria. 
 The investigator will maintain a screening log to  record details of all subjects screened and to 
confirm eligibility or record reason for screen failure, as applicable. 
 At screening, subjects will be provided with a card stating that they are participating in a trial 
and giving contact details of relevant site staff th at can be contacted in case of emergency.  
 Adherence to the trial design requirements, including those specified in the flowchart, is 
essential and required for trial conduct.  
 The investigator must ensure to keep regular co ntact with each subject throughout the entire 
trial, and always have updated contact information. Even if a visit is missed and it is not 
possible to reschedule, every effort must be made to have all subjects followed for the primary 
endpoint and AEs. 
 It is the responsibility of the investigator to schedule the visits and contacts as per the protocol 
flowchart (Section 1.2) and to ensure they take place. See Section 6.4 for treatment compliance. 
 Suggested order of assessments: 
 electrocardiogram (ECG) and vital signs 
 blood samples 
 other assessments 
 Diaries will include the following in relation to the visit they support: 
 Reminders: 
o to attend visit fasting (see flowchart in Section 1.2) 
o to collect first morning urine on day prior to visit and on the day of the visit (see 
Table 10-1 ) 
o to return trial product at  next site visit 
o to return diary at next site visit 
 Instruction on how to use the diary 
 Information to be collected: 
o date of first dose of trial product 
o date and time of last dose prior to PK visit 
o hypoglycaemic events (according to Appendix 6 in Section 10.6) 
o health issues 
 Review of diaries, ECG and laboratory reports mu st be documented either on the documents or 
in the subject's source documents. If clarification of entries or discrepancies in the diary is 
needed, the subject must be questioned, and a conclusion made in the subject's source 
documents. Care must be taken not to bias the subject. 
 Repeat samples may be taken for technical issu es and unscheduled samples or assessments may 
be taken for safety reasons. Please refer to Appendix 2 (Section 10.2) for further details on 
laboratory samples. 
 Source data of clinical assessments performed and recorded in the CRF must be available and 
D699B@B.99F/2A52@B/720AN@:2160.9?20<?1@ Additional recordings to be considered source data CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 39 of 93 
 
include but are not limited to laboratory reports, ECG, diary recordings and clinical outcome 
assessments. Ensure to transcribe the following into the CRF: 
o All information from the diary 
o Evaluations of ECGs 
8.1 Efficacy assessments  
Planned time points for all efficacy assessments are provided in the flowchart (Section 1.2) and in 
Appendix 2 (Section 10.2). 
8.1.1 Clinical efficacy laboratory assessments 
All protocol-required laboratory assessments, as defined in Appendix 2 (Section 10.2), must be 
conducted in accordance with the fl owchart and the laboratory manual. 
8.1.2 Body weight 
Body weight will be measured and recorded as specified in the flowchart (Section 1.2).  
Body weight should be measured without shoes and only wearing light clothing and recorded in the 
eCRF in kilogram [kg] or pound [lb] with a pr ecision of 1/10 unit (e.g. 62.2 / 137.2 lb). BMI will be 
calculated in the eCRF. 
8.1.3 Waist circumference 
Waist circumference will be measured and rec orded as specified in the flowchart (Section 1.2). 
Waist circumference  is defined as the minimal abdominal circumference located midway between 
the lower rib margin and the iliac crest and will be measured using a non-stretchable measuring 
tape. The measurement of waist circumference should be performed and recorded in the eCRF to 
the nearest Â½ cm or Â¼inch. The waist circumference should be measured in a standing position with 
an empty bladder and wearing light clothing with accessible waist. The subject should be standing 
with arms down their side and feet together. The measuring tape should touch the skin but not 
compress soft tissue. The subject should be asked to breathe normally, and the measurement should 
be taken when the subject is breathing out gently. 
8.2 Safety assessments  
Planned time points for all safety assessmen ts are provided in the flowchart (Section 1.2).  
A concomitant illness  is any illness that is already present at the time point from which AEs are 
collected or found as a result of a screening p rocedure or other trial procedures performed before 
exposure to trial product.  
Medical history is a medical event that the subject experienced prior to the time point from which 
AEs are collected. 
Only relevant and significant medical history including COVID-19 as judged by the investigator 
should be recorded in the eCRF at the screening vi sit. Findings of specific medical history (diabetes CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 40 of 93 
 
history, comorbidities and history of cardiovascular  disease) should de described in designated 
forms. 
In case of an abnormal and clinically significant finding fulfilling the definition of a concomitant 
illness or medical history, the investigator must record the finding on the Medical History/ 
Concomitant Illness form in the eCRF. 
Any new finding fulfilling the AE definition (see Appendix 3 (Section 10.3)) during the trial and 
any clinically significant worsening from baseli ne must be reported as an AE (see Section 8.3). 
8.2.1 Physical examinations 
 A physical examination will include assessments of the following: General appearance, thyroid 
gland, cardiovascular system, respiratory system,  gastrointestinal system incl. mouth, central 
and peripheral nervous system, and musculoskeletal system. 
 Investigators should pay special attention to clinic al signs related to previous serious illnesses. 
 Height will be measured and recorded as specified in the flowchart (Section 1.2). 
 Height should be measured without shoes in ce ntimetres or inches and recorded to nearest Â½ cm 
or Â¼ inch. 
8.2.2 Vital signs 
 Pulse rate as well as systolic and diastolic blood pressure will be assessed as specified in the 
flowchart (Section 1.2). 
 Blood pressure and pulse rate measurements should be  preceded by at least 5 minutes of rest for 
the subject in a quiet setting without distract ions (e.g. no use of television, cell phones). 
 Blood pressure and pulse rate measurements wi ll be assessed sitting with a completely 
automated device. Manual techniques must be used only if an automated device is not available. 
 Blood pressure will consist of 3 systolic and diastolic blood pressure measurements with 
intervals of at least 1-2 minutes. An additional fourth blood pressure measurement must be performed if the first two readings on systolic or diastolic blood pressure differ by >10 mmHg.  
Only the last 2 systolic and last 2 diastolic blood pressure readings must be recorded in the 
eCRF. The eCRF will then calculate the mean for systolic and diastolic blood pressure.  
 Pulse rate will be measured in connection to the blood pressure measurements. Record the pulse 
rate for the last 2 blood pressure measurements in th e eCRF. The pulse rate is to be recorded as 
the mean of the last 2 measurements. 
8.2.3 Electrocardiograms 
12-lead ECG will be obtained as outlined in the flowchart (Section 1.2) using an ECG machine that 
automatically calculates the heart rate and measures PR, QRS, QT and QTc intervals.  
The ECGs will be collected for central storage for potential future assessment. This is to have the 
possibility to go back and evaluate previous ECG data in case of unforeseen or abnormal 
observations that could indicate safety finding s or for future scientific purposes related to 
semaglutide, T2D, CV outcome or related diseases.  
Local review for clinically significant abnormal findings must be performed by the investigator. ECG must be performed according to the manual from the supplier. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 41 of 93 
 
8.2.4 Eye examination 
Subjects with uncontrolled and potentially unstable diabetic retinopathy or maculopathy are not 
eligible as this indicates retinopathy that has recen tly progressed to a level that requires intervention 
or is approaching intervention but has yet to be brought under control. 
Results of an eye examination performed by an opht halmologist or another suitably qualified health 
care provider (e.g. optometrist) must be available and evaluated by the investigator before 
randomisation to assess eligibility. The eye examination should be performed as a fundus 
photography (e.g. 2-field 60 degree or better, colour or red-free) or by slit-lamp biomicroscopy 
examination (e.g. using a pre-corneal or corneal contact lens examination). Pharmacological 
pupil-dilation is a requirement unless using a digital fundus photography camera specified for 
non-dilated examination. 
If the subject had such an eye examination performed within 90 days prior to screening, the 
investigator may base his/her evaluation upon the re sults of that examination. The examination must 
be repeated before randomisation if the subject has experienced worsening of visual function since 
the last examination. If the applicable eye examinat ion was performed before the subject signed the 
informed consent form, it must be documented that the reason for performing the examination was not related to this trial. 
After randomisation, an eye examination performed according to the above must be completed as 
per the flowchart (Section 1.2). An eye examination performed within 2 weeks prior to the 
applicable visits is acceptable, provided that no clinical symptoms suggestive of eye disease have 
occurred in the meantime in case of which a new examination must be completed. The investigator 
should indicate the outcome of each eye examination in the CRF. 
The fundus photography or slit-lamp biomicroscopy examination should be used for evaluation of 
retinopathy or maculopathy. Additional examinations (e.g., optical coherence tomography and/or 
best corrected visual acuity) can be performed as a supplement for further evaluation. However, in 
this trial, additional eye examinations including the optical coherence tomography and/or best 
corrected visual acuity, cannot replace the fundus photography or slit-lamp biomicroscopy 
examination. 
Relevant findings prior to randomisation must be recorded as concomitant illness/medical history. 
Relevant findings occurring after randomisation should be reported as an AE (please refer to 
Section 8.3). 
Germany and United States of America: for country-specific requirements, please see Appendix 8 
(Section 10.8). 
8.2.5 Clinical safety laboratory assessments 
All protocol-required laboratory assessments, as defined in Appendix 2 (Section 10.2), must be 
conducted in accordance with the laboratory manual and the protocol flowchart. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 42 of 93 
 
8.3 Adverse events and serious adverse events 
The investigator is responsible for detecting, doc umenting, recording and following up on events* 
that meet the definition of an AE or SAE. 
*including AEs of COVID-19, irrespective of seriousness. Note: Suspected COVID-19 should be 
reported if the clinical presentation is suggestive of COVID-19, even in the absence of a COVID-19 
test or without a positive COVID-19 test result. In the absence of clinical symptoms, a positive 
COVID-19 test (antigen or antibody) should be reported, if available.  
The definition of AEs and SAEs can be found in Appendix 3 (Section 10.3), along with a 
description of AEs requiring additional data collection. 
Some AEs require additional data collection on a specific event form. This always includes 
medication error, misuse and abuse of IMP. Th e relevant event(s) are listed below in Table 8-1 . 
Table 8-1 AEs requiring additional data co llection (serious and non-serious AEs) 
Event type   
Diabetic retinopathy 
Gallbladder disease 
Hepatic Event 
Neoplasm 
Acute pancreatitis 
Acute kidney injury 
Medication error, misuse and abuse  
A detailed description of the events mentioned in the above table can be found in Appendix 3 
(Section 10.3). 
Hypoglycaemic episodes 
Hypoglycaemic episodes require additional data collection on a hypoglycaemic episode form. As 
opposed to AEs requiring additional data collection ( Table 8-1 ), non-serious hypoglycaemic 
episodes do not require an AE form to be filled in . If the hypoglycaemic episode fulfils the criteria 
for an SAE, then, in addition to the hypoglycaemic episodes form, an AE form and a safety 
information form must be filled in, please refer to Appendix 3 (Section 10.3). For more information 
on hypoglycaemic episodes, please refer to Appendix 6 (Section 10.6). 
8.3.1 Time period and frequency for collecting AE and SAE information 
All AEs and SAEs must be collected from the scre ening visit and until the follow-up visit (V17) at 
the time points specified in the flowchart (Section 1.1).  
Medical occurrences that take place or have onset prior to the time point from which AEs are 
collected will be recorded as concomitant illn ess/medical history. AE and SAE reporting timelines 
can be found in Appendix 3 (Section 10.3). All SAEs must be recorded and reported to Novo 
Nordisk or designee within 24 hours, and the investigator must submit any updated SAE data to 
Novo Nordisk or designee within 24 hours of it being available. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 43 of 93 
 
Investigators are not obligated to actively seek for  AE or SAE in former trial subjects. However, if 
the investigator learns of any SAE, including a death, at any time after a subject has been 
discontinued from/completed the trial, and the investigator considers the event to be 
possibly/probably related to the trial product or relate d to trial participation, the investigator must 
promptly notify Novo Nordisk. 
8.3.2 Method of detecting AEs and SAEs 
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for 
completing and transmitting SAE reports are provided in Appendix 3 (Section 10.3). 
Care should be taken not to introduce bias when  detecting AEs and/or SAEs. Open-ended and non-
leading verbal questioning of the subject is the preferred method to inquire about events. 
8.3.3 Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs should be followed until final outcome of the event or the 
subject is lost to follow-up as described in Section 7.3. Further information on follow-up and final 
outcome of events is given in Appendix 3 (Section 10.3).  
8.3.4 Regulatory reporting requirements for SAEs 
Prompt notification by the investigator to Novo N ordisk or designee of a SAE is essential so that 
legal obligations and ethical responsibilities towards the safety of subjects and the safety of a trial 
product under clinical investigation are met.  
Novo Nordisk has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a tria l product under clinical investigation. Novo Nordisk 
will comply with country-specific regulatory requirements relating to safety reporting to the 
regulatory authority, Institutional Review Board (IRB)/ Independent Ethics Committee (IEC), and 
investigators. This also includes suspected unexpected serious adverse reactions (SUSAR ). 
An investigator who receives an investigator safety report describing a SAE or other specific safety 
information (e.g. summary or listing of SAEs) from N ovo Nordisk will review and then file it along 
with the investigator's brochure and will notif y the IRB/IEC, if appropriate according to local 
requirements. 
8.3.5 Pregnancy 
Details of pregnancies in female subjects will be  collected after first exposure to trial product and 
until pregnancy outcome. 
If a female subject becomes pregnant, the investigator should inform Novo Nordisk within 14 
calendar days of learning of the pregnancy and sh ould follow the procedures outlined in Appendix 4  
(Section 10.4). 
8.3.6 Cardiovascular and death events 
Cardiovascular and death even ts will be handled and reported according to Section 8.3. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 44 of 93 
 
8.3.7 Technical complaints 
Technical complaints will be collected for all products listed on the technical complaint form. 
Instructions for reporting technical complaints can be found in Appendix 5 (Section 10.5). 
In order for Novo Nordisk to perform a complete investigation of reported SAEs, Novo Nordisk 
might ask the investigator to complete a technical complaint form.  
8.4 Treatment of overdose 
There are no specific antidotes to semaglutide. Effects of overdose with semaglutide may be 
associated with GI disorders. 
In the event of an overdose, the investigator should closely monitor the subject for overdose-related 
AE/SAE and laboratory abnormalities, and appropri ate supportive treatmen t should be initiated 
according to the subject @N096;60.9@64;@.;1@F:=A<:@=?<9<;421=2?6<1<3</@2?C.A6 <;.;1
treatment for these symptoms may be necessary, taking into account the long half-life of oral 
semaglutide of approximately one week.  
Accidental overdose must be reported as a medication error. Intentional overdose must be reported 
as misuse and abuse, please refer to Section 8.3 and Appendix 3 (Section 10.3) for further details. 
For more information on overdose, also consult the current version of the oral semaglutide 
investigator's brochure. 
8.5 Pharmacokinetics 
 Single blood samples for measuring plasma conc entration of semaglutide will be drawn on 
visits specified in the flowchart (Section 1.2) and in Appendix 2 (Section 10.2). 
 Subject must be instructed to withhold their trial treatment in the morning of the clinic visit until 
blood sampling has been performed. 
 The exact timing (date and time) of obtaining the pharmacokinetic (PK) sample must be 
recorded on the laboratory form. 
 The exact timing (data and time) of last oral semagl utide dose must be recorded in the eCRF in 
relation to the PK sample 
 The purpose of measuring plasma semaglutide levels is to conduct exposure-response, to 
evaluate the dose response and the adherence to the treatment. 
 Blood samples for PK assessments must be co llected, handled and shipped according to the 
description in the laboratory manual supplied by the central laboratory. The bioanalysis of semaglutide PK will be performed by a spec ial laboratory. Semaglutide PK samples will be 
stored at the special laboratory responsible for PK until final Clinical Trial Report (CTR) in case 
Novo Nordisk requests further analysis of the PK  samples. Details of th e bioanalysis will be 
outlined in a bioanalytical study plan issued by the special laboratory. Bioanalysis of plasma 
samples for semaglutide will be carried out using a validated LC-MS/MS assay. 
8.6 Pharmacodynamics 
Not applicable for this trial. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 45 of 93 
 
8.7 Genetics 
Not applicable for this trial.  
8.8 Biomarkers 
Not applicable for this trial. 
8.9 Immunogenicity assessments 
Anti-semaglutide antibodies 
Blood samples for measurements of binding antibodies against semaglutide will be collected at pre-
specified time points according to Appendix 2 (see Section 10.2) and must be completed pre-dose at 
V2. Blood samples will be collected, but anti-semaglutide antibodies will only be analysed by Novo 
Nordisk or a special lab appointed by Novo Nordisk if deemed necessary for clarification of 
unexpected drug exposure or other safety issues that may be related to antibody formation. If anti-
semaglutide binding antibodies are measured, data as well as assay method description will be 
reported outside the CTR for this trial.  
Procedures for sampling, handling, storage, labelling  and shipment of samples must be performed in 
accordance with the laboratory manual. 
Residual antibody samples will be retained (please refer to Appendix 7, Section 10.7). 
8.10 Health economics 
Not applicable for this trial. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 46 of 93 
 
9 $$#$ #"$ #  
9.1 Statistical hypotheses 
Four confirmatory hypotheses will be evaluated based on the primary and secondary estimand. For 
the primary endpoint, change in HbA 1c from baseline to week 52, the following confirmatory one-
sided hypothesis of superiority will be tested for both oral semaglutide 50 mg and 25 mg versus oral 
semaglutide 14 mg. Let the mean treatment difference (higher dose of oral semaglutide - oral 
@2:.49BA612:4/21236;21.@R)52;B99  (H 0) and alternative (H A) hypotheses to be tested are: 
H0RI
 -point against H AR
 -point 
For the confirmatory secondary endpoint, change in body weight from baseline to week 52, the 
following confirmatory one-sided hypothesis of superi ority will be tested for both oral semaglutide 
50 mg and 25 mg versus oral semaglutide 14 mg: 
H0RI
84.4.6;@A AR
84  
Operationally, the hypotheses will be evaluated by two-sided tests. 
Multiplicity adjustment 
Adjustment for multiplicity associated with the testing of the four confirmatory hypotheses will be 
done using the weighted Bonferroni-based closed testing procedure described in Bretz et al.11 and 
outlined in Figure 9-1 . The type I error will be preserved in the strong sense at a nominal two-sided 
5% level. The first hypothesis to be tested is superiority of oral semaglutide 50 mg vs 14 mg on 
change from baseline in HbA 1c. It will be tested at the overall significance level (5%) while 
allocating 0% local significance level to the remaining of the hypotheses. For this hypothesis, and in 
general, if a hypothesis is confirmed, then the signif icance level will be reallocated according to the 
weight and the direction of the arrows going from the confirmed hypothesis to the next hypotheses 
as specified in Figure 9-1 . Each of the four hypotheses will be tested at their updated local 
@64;6360.;0292C29Q -local). This process will be repeated  until no further hypotheses can be 
confirmed.  
Superiority will be considered confirmed if th e mean treatment difference is supporting the 
corresponding alternative hypothesis and the two-sided p-value from the primary analysis is strictly 
below its local two-sided significance level as de fined by the closed testing procedure. This is 
equivalent to using a one-sided p- C.9B2;<:6;.9Q

.;1.<;2 -sided 2.5% overall 
significance level in the closed testing procedure. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 16 September 2022 Novo Nordisk
Trial ID: NN9924-4635 Version: 7.0
     Status: Final
     Page: 47 of 93
Figure 9-1 Graphical illustration of  the closed testing procedure
)52<C2?.99@64;6360.;0292C29<3Q

AD< -sided) is initially allocated to the hypothesis of superiority of oral 
semaglutide 50 mg vs 14 mg on change from baseline in HbA 1c(top left box). If a hypothesis is confirmed, the local 
@64;6360.;0292C29Q -local) will be reallocated according to the weight given by the directed edges between boxes 
(hypotheses).
9.2 Sample size determination
The sample size calculation was made considering th e power for jointly confirming the superiority 
hypotheses with respect to HbA 1cfor both oral semaglutide 50 mg and 25 mg versus oral 
semaglutide 14 mg for the primary estimand and to ensure a sufficient number of subjects will be 
exposed to assess safety and tolerability of the higher dose levels.
The sample size is calculated using the calcPower function in the R package, gMCP12using 10000 
simulations. All of the four pre-specified confirmatory tests are assumed to be independent. 
Because some of the tests are positively correlate d, the assumption of independence is viewed as 
conservative.
For change from baseline in HbA 1c, exposure-response modelling i ndicates a treatm ent difference 
vs 14 mg oral semaglutide of -0.52%-point and -0.33%-point for oral semaglutide 50 mg and 
25 mg, respectively, in the population with baseline HbA 1cbetween 8.0% and 10.5% and baseline 
$ I 5kg/m2assuming that all subjects remain on trial treatment and do not initiate rescue 
medication. For change from baseline in body weight, treatment differences versus 14 mg oral 
semaglutide are predicted to be below -3.6 kg and -1.8 kg for oral semaglutide 50 mg and 25 mg, 
respectively.
In the sample size calculation, the assumed treatment effect will be adjusted for the anticipated 
premature trial treatment discontinuation, change in dose and use of rescue medication during 52
weeks. Across the PIONEER phase 3a trials, 15 % to 20% of the subjects had discontinued trial 
treatment by week 52 with oral semaglutide 14 m g. Based on data from the PIONEER phase 3a 
trials for subjects with baseline HbA 1c/2AD22;
.;1
.;1/.@296;2$ I 5kg/m2,
similar to the inclusion criteria in this trial, it is anticipated that approximately 12% of subjects 
randomised to oral semaglutide 14 mg will prematurely discontinue trial treatment and that 12% 
will initiate rescue medication. Data from the 20  mg and 40 mg dose arms in the phase 2 trial 
(NN9924-3790) suggest that with oral semaglut ide 25 and 50 mg, an additional 10-15% of the 
subjects may discontinue trial treatment, however, this was based on another dose escalation 
approach with a higher initial dose level. The procedures described in Section 6.6are anticipated to 
Body weight (kg)
Superiority
Î±local=0
HbA1c (%-point)
Superiority
Î±local=0
Body weight (kg)
Superiority
Î±local=0
HbA1c (%-point)
Superiority
Î±local=0.05
Oral semaglutide 25 mg
vs. Oral semaglutide 14 mg
Oral semaglutide 50 mg
vs. Oral semaglutide 14 mg
Â½
Â½
1
1CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 48 of 93 
 
reduce the proportion of subjects prematurely discontinuing trial treatment with the higher dose 
levels. The proportion of subjects initiating rescue medication for the higher dose levels is assumed 
to be less than with the 14 mg dose.  
It can be assumed that subjects discontinuing on oral semaglutide 14 mg would also do so if 
randomised to 25 mg or 50 mg. For the 12% of subj ects expected to discontinue already at 14 mg, a 
treatment difference of zero is therefore assume d. For the remaining subjects discontinuing on 
25 mg and 50 mg, a residual benefit of the higher dose could be expected depending on time of 
discontinuation. On the other hand, if discontinuing, subjects may initiate another treatment inferior 
to oral semaglutide 14 mg. As described in Section 6.6, dose reduction is allowed to accommodate 
subject tolerability. Collectively, a treatment difference of zero is assumed for the excess proportion 
of subjects assumed to reduce dose or prematurely disc ontinue treatment with the higher dose levels 
as well. The treatment difference is assumed to be reduced by 75% for subjects initiating rescue 
medication.  
The sample size calculation is based on the assu mptions that 20% of the subjects reduce dose or 
discontinue trial treatment prematurely with the hi gher dose levels and that 12% initiate rescue 
medication with 14 mg oral semaglutide. Hereby, the adjusted treatment difference (TD) will be: 
ÂÂÂÂÂÂÂÜ¦Ü¶ àµ Í²Ç¤Í¸ÍºÜ¦Ü¶ÚàµÍ²Ç¤Í³Í´ÚÍ²Ç¤Í´Í·Ü¦Ü¶ÚàµÍ²Ç¤Í´Í²ÚÍ²Ü¦Ü¶Ú  
The adjusted TD are -0.38 %-point and -0.23 %-point for HbA 1c and of -2.6 kg and -1.3 kg for body 
weight for oral semaglutide 50 and 25 mg, respectively. The power to jointly confirm HbA 1c 
superiority for both dose levels will be 89% with 1620 subjects randomised and a randomisation 
ratio of 1:1:1. The assumed common standard deviations  for the change from baseline endpoints are 
based on data from subjects with baseline HbA 1c between 8.0% and 10.5%  and baseline BMI 
I5kg/m2 in PIONEER 2 (trial NN9924-4223) and 3 (trial NN9924-4222). Calculated powers for 
individual hypotheses are presented in Table 9-1 . 
Table 9-1 Calculated powers for individual hypotheses 
 
 HbA 1c superiority Body weight superiority 
Treatment dose 50 mg 25 mg 50 mg 25 mg 
Power  >99% 89% >99% 86% 
Table 9-2  shows the sensitivity of the power under different deviations from the above assumptions 
with a fixed sample size of 1620 subjects. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 49 of 93 
 
Table 9-2 Power for jointly confirming HbA 1c superiority under various assumptions 
TD HbA 1cS  
(%-=<6;AS   ),S   
84S  &?<=<?A6<;S   
16@0<;A6;B21S   Adj. TD HbA 1cS  
(%-=<6;AS   17),S   
84S  Standard 
12C6.A6<;S   &<D2?S   

:4S   :4S   
:4S   :4S   Both 1<@2@S   
:4S   :4S   
:4S   :4S   HbA 1cS  ,S  S  
-0.52 -0.33 -3.6  -1.8  S   -0.36 -0.22  -2.4  -1.2  S  S  84 S 
-0.52  -0.33  -3.6  -1.8  
S   -0.38  -0.23 -2.6 -1.3 S   
S  S  
-0.52  -0.33  -3.6 -1.8 *   -0.38 -0.23  -2.6  -1.3  *  *  	
*  
-0.52  -0.33  -3.6  -1.8  
S   -0.38 -0.23  -2.6  -1.3  S   
S  S  
-0.52 -0.33  -3.6  -1.8  S   -0.39  -0.24 -2.6  -1.3  S  S  S  
-0.50  -0.30  -3.3  -1.5  S   -0.33  -0.20  -2.2 -1.0  S  S  77 % 
-0.50 -0.30  -3.3  -1.5  
S   -0.36  -0.21  -2.3  -1.1  S  S  83 % 
-0.50  -0.30  -3.3  -1.5 S   -0.37  -0.22  -2.4 -1.1  S  S  85 % 
Assuming 12% on rescue medication with 14 mg oral semaglutid e. The highlighted scenario has been chosen for the 
sample size calculation. 
1620 subjects will be randomly assigned to trial treatment.  
9.3 Populations for analyses 
The following populations are defined: 
Population Description 
Full analysis set (FAS) All subjects randomised. Subjects contribute to a treatment group based on the 
trial treatment they were randomised to receive. 
Safety  analysis set (SAS) All subjects who receive at least 1 dose of  trial treatment. Subjects contribute to 
a treatment group based on the trial treatment they actually received. 
The FAS will be used in the evaluation of the efficacy endpoints, the SAS will be used for the 
evaluation of the safety endpoints, exclusively.  
Data selections and observation periods 
Unless subjects withdraw their informed consent, d ata collection will continue for the planned full 
duration of the trial for the individual subject. The full duration of the trial is defined as up to and 
including the follow-up visit (V17) for subjects co mpleting trial treatment and subjects who have 
discontinued trial treatment prematurely. 
As described in Section 3.1 the trial objectives relating to efficacy will be addressed using two 
different types of estimands. The primary and se condary estimands applying a treatment policy 
strategy to all intercurrent events and the additional supportive estimands applying a hypothetical 
strategy to the intercurrent events of premature trial treatment discontinuation and initiation of 
additional anti-diabetic medicati on. The handling of the intercurrent events with respect to data 
collection and analysis is specified in Table 9-3 . CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 50 of 93 
 
Table 9-3 Handling of intercurrent events for the estimands 
Intercurrent event  Primary and secondary estimands Additional supportive estimands 
Premature trial treatment 
discontinuation 
Data collected after the intercurrent 
event is used in analysis in line with a 
treatment -policy strategy, i.e. 
disregarding the occurrence of the 
intercurrent event  Data collected after the intercurrent 
event will be excluded and treated as 
missing in  analysis, i.e. using a 
hypothetical strategy  Initiation of additional anti-diabetic 
medication 
Change of dose  Data collected after the intercurrent 
event and used in anal ysis in line with 
a treatment -policy strategy, i.e. 
disregarding the occurrence of the 
intercurrent event 
Additional anti-diabetic medication is defined as new anti-diabetic medication and/or intensification 
of anti-diabetic medication initiated at or after ra ndomisation and before planned end of treatment. 
Rescue medication is used to designate addition al anti-diabetic medication initiated while on trial 
treatment, i.e. before last dose of trial product. 
Observation periods will be used to select data for anal yses in line with the strategies applied for the 
intercurrent events. Subjects and data to be used in  an analysis will be selected in a two-step 
manner: 
 First, subjects will be selected based on the specified analysis set. 
 Second, data points on the selected subjects from th e first step will be selected based on the 
specified observation period. 
For the efficacy and safety evaluations, three different observation periods will be defined: 
 The in-trial  observation period J the time period from when a subject is randomised until the 
final scheduled visit, including any period after initiation of additional anti-diabetic medication 
or discontinuation of trial treatment. 
 The on-treatment  observation period J the time period when a subject is on trial treatment, 
including any period after initiation of rescue medication. 
 The on-treatment without rescue medication  observation period J the time period when a 
subject is on trial treatment, excluding any period after initiation of rescue medication. 
The in-trial  observation period begins at the date of random isation and ends at the final scheduled 
visit, which can be one of the below: 
 the follow-up visit (V17) for subjects who comple te treatment and for subjects who discontinue 
trial treatment prematurely 
 the last contact for subjects who withdraw from trial, are lost to follow-up or die 
The on-treatment  observation period begins at the date of fi rst dose of trial treatment; the end date 
depends on the assessment being evaluated: 
 For all efficacy assessments and certain safety assessments (laboratory assessments, physical 
examination and vital signs), a plus-3-day window (i.e. the 3-day visit window) is used and the 
period ends at the first of the following time points:  
 last dose of trial treatment plus a 3-day window  
 end of the in-trial observation period CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 51 of 93 
 
 For the remaining safety assessments (eye examination categories, AEs, and hypoglycaemic 
episodes), a plus-38-day window (i.e. the 5-week follow-up period plus the 3-day visit window) 
is used and the period ends at the first of the following time points: 
 the follow-up visit (V17) 
 the last dose of trial treatment +38 days  
 end of the in-trial observation period 
The on-treatment without rescue medication  observation period begins at the date of the first 
dose of trial treatment and ends at the first of the following time points: 
 end of the on-treatment observation period 
 initiation of rescue medication (if any) 
For the efficacy endpoints, the primary and secondary estimands will be evaluated based on data 
from the in-trial observation period and the additional supportive estimands will be evaluated based 
on data from the on-treatment without rescue medica tion observation period thereby selecting data 
in line with the strategies applied for the intercurrent events as shown in Table 9-3 . The safety 
evaluation will primarily be based on the on-tre atment observation period, except for deaths and AE 
types with potentially long latency between onset and diagnosis, for which the in-trial observation 
period will be used. The observation period determin es what data subjects contributes with to a 
specific analysis. Baseline values are by defi nition included in all observation periods; other data 
points collected outside the observation period used for an analysis will be considered missing. 
Before data are locked for statistical analysis, a re view of all data will take place. Exclusion of data 
from analyses should be used restrictively, and normally no data should be excluded from the FAS. 
The subjects or observations to be excluded, and the reasons for their exclusion must be documented before unblinding. The subjects and observations excluded from analysis sets, and the 
reason for this, will be described in the clinical trial report. 
9.4 Statistical analyses 
The statistical analysis plan (SAP) will be finalis ed prior to database lock or potential partial 
database lock, and it will include a more technica l and detailed description of the statistical analyses 
described in this section. This section is a sum mary of the planned statistical analyses of the most 
important endpoints, including the primary and confirmatory secondary endpoints. 
9.4.1 General considerations 
Data from all sites will be analysed and reported together. 
In statistical analyses where stratification is a ccounted for, the background medication at screening 
will be included based on the actual information collected through the eCRF. In case of missing 
eCRF information, the information collected from the IWRS system will be used.  
The latest available measurement, at or prior to the ra ndomisation visit, will be used as the baseline 
measurement. If no measurement(s) have been obtained, at or prior to randomisation, the baseline 
value will be left missing.  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 52 of 93 
 
Results from a statistical analysis will as a minimum be presented by the estimated treatment 
contrasts for each high dose vs. 14 mg oral s emaglutide with associated two-sided 95% confidence 
intervals and p-values corresponding to two-sided tests of no difference. 
Missing data 
The amount of missing data when estimating the prima ry and secondary estimands (i.e. data that are 
not available even though all efforts were made to ensure that subjects stayed in the trial regardless 
of premature discontinuation of trial treatment or in itiation of additional anti-diabetic treatment) is 
expected to be low. At week 52, the proportion of subjects with missing data was 5-7% across trials 
in the PIONEER programme. Missing data will be mi ssing mainly be due to subjects withdrawing 
consent or being lost to follow-up. In the statistical analyses, missing data will be handled in line 
with the strategies applied for the pre-defined intercurrent events. 
9.4.2 Primary endpoint 
The primary endpoint is the change in HbA 1c (%-point) from baseline (week 0) to week 52. 
Primary analysis for the primary estimand 
The primary estimand defined in Section 3.1 will be estimated based on the FAS using week 52 
measurements from the in-trial observation period. Th e primary statistical analysis will be a pattern 
mixture model using multiple imputation to handl e missing data assuming that the missing data 
mechanism is missing at random (MAR) within the groups used for imputation. Imputation of 
missing week-52 data will be done within 6 groups of subjects defined by randomised treatment 
arm, and whether subjects at week 52 (i) are st ill on treatment and have not initiated rescue 
medication or (ii) have discontinued treatment or in itiated rescue medication. It is hereby assumed 
that the likely values of what the missing data would have been if available are best described by 
information from subjects who at week 52 are si milar in terms of randomised treatment arm and 
trial treatment discontinuation/rescue medication st atus. For each imputation group, an analysis of 
covariance model (ANCOVA) with  stratification factor and regi on as factors and baseline HbA 1c as 
covariate will be used to impute 1000 values for each subject with missing week 52 data. For the 
imputation groups where the subjects have disconti nued treatment or initiated rescue medication the 
time (days) from randomisation until discontinuation or  initiation of rescue medication will also be 
included as a covariate. The 1000 complete data sets will be analysed using an ANCOVA with 
treatment, stratification factor and region as factors and baseline HbA 1c as covariate. The results 
</A.6;213?<:.;.9F@6;4A521.A.@2A@D699/20<:/6;21B@6;4'B/ 6;N@?B9213 to draw inference. 
Sensitivity analysis for the primary estimand  
In line with ICH E9 (R1), sensitivity analyses will be performed investigating the robustness of the 
conclusions made on the basis of the primary an alyses towards the impact of missing data. 
Tipping-point multiple imputation analysis : A two-dimensional tipping point sensitivity analysis 
will be used to address the assumption of MAR within imputation groups. Subjects with missing 
data will be assumed to have a worse outcome in the 25 mg and 50 mg treatment arms and a better 
outcome in the 14 mg arm compared to the imputations in the primary analysis. Missing data will 
first be imputed as in the primary analysis. Second ly, penalties will be added to or subtracted from 
the imputed week-52 values. The approach is to gradually increase these penalties independently in CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 53 of 93 
 
the treatment arms until the confirmed HbA 1c conclusion from the primary analysis is changed. For 
each hypothesis tested, the values of the penalties  that changes the conclusion will be used to 
evaluate the robustness of the primary analysis results.    
Return to baseline multiple imputation analysis:  subjects with missing data at week 52 will have 
their change from baseline value imputed as 0 plus a random error. The error is randomly drawn 
from a normal distribution with a mean of 0 and a va riance equal to the re sidual variance estimated 
from the MMRM for observed values of change from baseline in HbA 1c, adjusted for the same 
covariates and factors as in the primary analysis. For missing values from patients who are still on 
treatment, it will be assumed that those data are missing at random and they will be imputed based 
on the observed data from the subjects who complete d the trial on treatment in the same treatment 
arm. 
Analysis for the additional estimand 
The additional estimand (Section 3.1) will be estimated based on the FAS using post-baseline 
measurements up to and including week 52 from the on-treatment without rescue medication 
observation period. The analysis for the additional estimand will be a Mixed Model for Repeated 
Measurements (MMRM). A restricted maximum likelihood will be used. The model will include all post baseline HbA
1c measurements collected at scheduled visits up to and including week 52 as 
dependent variables. The independent effects include d in the model will be treatment, stratification 
factor and region as categorical fixed effects and baseline HbA 1c as a covariate, all nested within 
visit. An unstructured covariance matrix for HbA 1c measurements within the same subject will be 
employed, assuming measurements from different subjects are independent. 
9.4.3 Secondary endpoints 
9.4.3.1  Confirmatory secondary endpoint 
The confirmatory secondary endpoint is the change in body weight (kg) from baseline (week 0) to 
week 52. 
Analysis for the secondary estimand  
The secondary estimand will be estimated in th e same way as for the primary endpoint with 
baseline HbA 1c replaced by baseline body weight as the covariate. 
Sensitivity analysis for the secondary estimand 
Sensitivity analyses similar to the ones performed  for the primary endpoint will be performed.  
Analysis for the additional estimand  
The additional estimand will be estimated in the sa me way as for the primary endpoint with baseline 
HbA 1c replaced by baseline body weight as the covariate.  
9.4.3.2  Supportive secondary endpoints 
For details on analyses of additional supportive sec ondary endpoints, please refer to the SAP, which 
will be completed prior to database lo ck or potential partial database lock. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 54 of 93 
 
9.4.4 Other safety analyses 
All safety analyses will be made on the safety an alysis set. The standard safety assessments (AEs, 
safety laboratory parameters, vital signs, etc.) will be reported descriptively; including any notable 
changes of clinical interest in laboratory parameters. 
9.4.5 Other analyse(s)  
For other analyse(s), please refer to the SAP.  
9.4.5.1  Pharmacokinetic modelling 
Population PK modelling and exposure-response analyses may be included to support dose 
selection and to explore the benefits of high vers us lower doses of semaglutide in subjects with 
T2D.  
The modelling will include data from all randomised  subjects that were exposed to semaglutide in 
this trial and might be performed as a meta-analy sis including data from historical trials. Actual 
dose and date of administration of last dose before PK sampling will be registered in the CRF and 
used in the analysis, together with actual time point for PK sampling.  
A modelling analysis plan will be prepared before  database lock or potential partial database lock 
for the trial, outlining details of the analysis. The re sults will be reported separately from the CTR. 
9.5 Interim analyses 
See Section 9.7 for details regarding partial database lock. 
9.6 Data monitoring committee  
Not applicable for this trial. 
9.7 Reporting of the main part of the trial 
A partial database lock will be performed at the end of the treatment period for all subjects, i.e., 
after the date of the last subject last treatment visit. A partial database lock is implemented to 
support potential earlier access of oral semaglutide 25 and 50 mg to the patient population expected 
to benefit from higher doses.  
All efficacy analyses will be performed based on the data from the partial database lock. No 
efficacy assessments are collected after last subj ect last treatment, and so unblinding of Novo 
Nordisk staff will be after all subjects have comp leted treatment. Therefore, efficacy results cannot 
be biased by the early unblinding. Impact on PK and safety evaluation after partial database lock is 
considered minor as most subjects will have completed the follow-up visit, and subjects and 
investigators remain blinded. Full analysis of PK and safety will be performed after the full 
database lock.  
The SAP will be finalised prior to partial database lock. A detailed plan for data handling, blinding, 
data analysis, and operational aspects of the partia l database lock and the database update will be 
finalised before the partial database lock.  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 55 of 93 
 
The result of the evaluation at partial database lock w ill not be shared with investigators or subjects 
before the full database lock, and only a minimu m number of Novo Nordisk staff will know the 
randomisation code at subject level. There will  be no change in study design regardless of the 
outcome of the evaluation at partial database lock.  
The database will be updated after the partial data base lock to include the remaining data. The full 
database lock will be performed, as per the usual procedures, after the date of the last subject last 
visit.  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 56 of 93 
 
10 %!! "$ %$$  !"$  #"$ #  
10.1 Appendix 1: Regulatory, ethical, an d trial oversight considerations 
10.1.1  Regulatory and ethical considerations 
 This trial will be conducted in accordance w ith the protocol and with the following: 
 Consensus ethical principles derived from international guidelines including the Declaration of 
Helsinki14 and applicable ICH Good Clinical Practice (GCP) Guideline15 
 Applicable laws and regulations 
 )52=?<A<0<96;3<?:210<;@2;A3<? :6;C2@A64.A<?N@/?<05B?2. @.==960./92. nd other relevant 
documents (e.g. advertisements) must be submit ted to an IRB/IEC and reviewed and approved 
by the IRB/IEC before the trial is initiated. 
 Regulatory authorities will receive the clinical trial application, protocol amendments, reports 
on SAEs, and the CTR according to national requirements. 
 Any amendments to the protocol will require  IRB/IEC approval before implementation of 
changes made to the trial design, except for chan ges necessary to eliminate an immediate safety 
hazard to trial subjects. 
 Before a site is allowed to start screening subjects, written notification from Novo Nordisk must 
be received. 
 The investigator will be responsible for: 
 providing written summaries of the status of the trial annually or more frequently in accordance 
with the requirements, policies, and procedures established by the IRB/IEC and/or regulatory 
authorities. 
 notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC 
procedures. 
 providing oversight of the conduct of the trial at the site and adherence to requirements of ICH 
guidelines, the IRB/IEC, and all other applicable local regulations. 
 ensuring submission of the CTR synopsis to the IRB/IEC. 
 reporting any potential serious breaches to the sponsor immediately after discovery. 
10.1.2  Financial disclosure 
Investigators and sub-investigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the trial and one 
year after completion of the trial. 
For US sites: Verification under disclosures pe r Code of Federal Regulations (CFR) of Financial 
Conflict of Interest. 
10.1.3  Informed consent process 
 The investigator or his/her representative will ex plain the nature of the trial to the subject and 
answer all questions regarding the trial. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 57 of 93 
 
 The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial.  
 Subjects must be informed that their participation is voluntary. 
 Subjects must be informed about their privacy rights.  
 Subjects will be required to sign and date a statement of informed consent that meets the 
requirements of local regulations, ICH guidelines15, Declaration of Helsinki14 and the IRB/IEC 
or site. 
 The medical record must include a statement that written informed consent was obtained before 
any trial related activity and the date when the written consent was obtained. The authorised 
person obtaining the informed consent must als o sign and date the informed consent form before 
any trial related activity. 
 The responsibility of seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically qualified person, in accordance with local requirements. 
 Subjects must be re-consented to the most current version of the informed consent form during 
their participation in the trial. 
 A copy of the informed consent form must be provided to the subject.  
10.1.4  Information to subjects during trial 
The site will be offered a communication packag e for the subject during the conduct of the trial. 
The package content is issued by Novo Nordisk. The communication package will contain written 
information intended for distribution to the subjects. The written information will be translated and 
adjusted to local requirements and distributed to the subject at the discretion of the investigator. The 
subject may receive .KD290<:2A<A52A?6.992AA2?L .;1.KA5.;8F<B3<?F<B?=.?A6 06=.A6<;92AA2?L
after completion of the trial. Further, the subject  may receive other written information during the 
trial.  
All written information to subjects must be sent to IRB/IEC for approval/favourable opinion and to 
regulatory authorities for approval or notif ication according to local regulations. 
10.1.5  Data protection 
 Subjects will be assigned a 6-digit unique iden tifier, a subject number. Any subject records or 
datasets that are transferred to Novo Nordisk wi ll contain the identifier only. No direct 
identifiers from the subject are transferred to Novo Nordisk. 
 The subject and any biological material obtained from  the subject will be identified by subject 
number, visit number and trial ID. Appropriate measures such as encryption or leaving out 
certain identifiers will be enforced to protect the identity of subjects as required by local, 
regional and national requirements.  
 The subject must be informed about his/her privacy  rights, including that his/her personal trial 
related data will be used by Novo Nordisk in accordance with local data protection law. The 
disclosure of the data must also be explained to the subject.  
 The subject must be informed that his/her medi cal records may be examined by auditors or 
other authorised personnel appointed by Novo Nordisk, by appropriate IRB/IEC members, and by inspectors from regulatory authorities. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 58 of 93 
 
10.1.6  Committees structure 
10.1.6.1  Novo Nordisk safety committee 
Novo Nordisk will perform ongoing safety surveillance. If new safety signals are identified, these 
will be evaluated by an internal safety committee.  The safety committee may recommend 
unblinding of any data for further analysis, and in this case an internal trial independent ad hoc 
group will be established in order to maintain the blinding of the trial personnel.  
10.1.7  Dissemination of clinical trial data 
Information of the trial will be disclosed at clinicaltrials.gov, clinicaltrialsregister.eu and 
novonordisk-trials.com. It will also be disclosed acc ording to other applicable requirements, such as 
those of the International Committee of Medical Journal Editors (ICMJE)16, the Food and Drug 
Administration Amendment Act (FDAAA)17, European Commission Requirements1, 18, 19 and other 
relevant recommendations or regulations. If a subject requests to be included in the trial via the 
Novo Nordisk e- :.690<;A.0A.AA52@2D2/@6A2@%<C<%<?16@8:.F16@09<@2A52 6;C2@A64.A<?N@
contact details to the subject. As a result of increasing requirements for transparency, some 
countries require public disclosure of i nvestigator names and their affiliations. 
The primary completion date (PCD) is the last asse ssment of the primary endpoint, and is for this 
trial last subject first treatment (LSFT) + 52 weeks corresponding to visit V14. If the last subject is 
withdrawn early, the PCD is considered the date when the last subject would have completed visit 
V14. The PCD determines the deadline for results disclosure at clinicaltrials.gov according to 
FDAAA. 
10.1.8  Data quality assurance 
10.1.8.1  Case report forms 
 Novo Nordisk or designee is responsible for the data management of this trial including quality 
checking of the data. 
 All subject data relating to the trial will be recorded on electronic CRFs  unless transmitted 
electronically to Novo Nordisk or designee (e.g . laboratory data). The investigator is responsible 
for verifying that data entries are accurate and co rrect by physically or electronically signing the 
CRF.  
 The following will be provided as paper CRFs: 
 Pregnancy forms  
 The following will be provided as paper CRFs to be used when access to the eCRF is revoked or 
the eCRF is temporarily unavailable: 
 AE forms  
 Safety information forms  
 Technical complaint forms (also to be used to report complaints on trial product not yet 
allocated to a subject) 
 <??20A6<;@A<A52'1.A.:.F/2:.12/FA526;C2@A64.A<?<? A526;C2@A64.A<?N@12924.A21
staff. An audit trail will be maintained in the CRF application containing as a minimum: the old 
and the new data, identification of the person enter ing the data, date and time of the entry and 
?2.@<;3<?A520<??20A6<; 30<??20A6<;@.?2:.12/FA526;C2@ A64.A<?N@12924.A21@A.33.3A2?A52CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 59 of 93 
 
date when the investigator signed the CRF, the CRF must be signed and dated again by the 
investigator. 
 The investigator must ensure that data is recorded in the CRF as soon as possible, preferably 
within 5 working days after the visit. Once data has been entered, it will be available to Novo 
Nordisk for data verification and validation purposes.  
10.1.8.2  Monitoring 
 The investigator must permit trial-related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents (original documents, 
data and records). Direct access includes permission to examine, analyse, verify and reproduce 
any record(s) and report(s) that are important to the evaluation of the trial. If the electronic 
medical record does not have a visible audit trail,  the investigator must provide the monitor with 
signed and dated printouts. In addition, the relev ant site staff should be available for discussions 
at monitoring visits and between moni toring visits (e.g. by telephone).  
 Trial monitors will perform ongoing source data ve rification to confirm that data entered into 
the CRF by authorised site personnel are accu rate, complete and verifiable from source 
documents; that the safety and rights of subjects are being protected, to monitor drug 
accountability and collect completed paper CRF pages, if applicable, and that the trial is being 
conducted in accordance with the currently app roved protocol and any other trial agreements, 
ICH GCP, and all applicable regulatory requirements. 
 Monitoring will be conducted using a risk-based approach including risk assessment, 
monitoring plans, centralised monitoring (r emote assessment of data by Novo Nordisk) and 
visits to sites.  
 $<;6A<?@D699?2C62DA52@B/720AN@:2160.9?20<?1@.;1<A52?@< B?02 data, e.g. the diaries to 
ensure consistency and/or identify omissions compared to the CRF.  
 An unblinded monitor will be responsible for th e reconciliation process set up for this trial. 
10.1.8.3  Protocol compliance 
Deviations from the protocol should be avoided. If deviations do occur, the investigator must 
inform the monitor without delay and the implica tions of the deviation must be reviewed and 
discussed. 
Deviations must be documented and explained in a protocol deviation by stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in th e eCRF or via listings from the trial database.  
10.1.9  Source documents 
 All data entered in the CRF must be verifiab le in source documentation other than the CRF. 
 If source data is entered directly in a paper CRF,  each data entry or clear series of data entries 
must be signed and dated separately by the trial staff making the entry. 
 The original of the completed diaries must not be removed from the site, unless they form part 
of the CRF and a copy is kept at the site. 
 Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. Source documents are filed at the site. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 60 of 93 
 
 Data reported on the paper CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the sour ce documents, or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer records. 
Also, current medical records must be available.  
  A:B@A/2=<@@6/92A<C2?63F@B/720AN@:2160.956@A<?F6;@<B? 021<0B:2;A@@B05.@@B/720AN@
medical record.  
 The investigator must document any attempt to obtain external medical information by noting 
the date(s) when information was requested, and who was contacted. 
 Definition of what constitutes source data can be found in a source document agreement at each 
site. There will only be one source document defined at any time for any data element. 
10.1.10  Retention of clinical trial documentation 
 Records and documents, including signed informed consent forms, pertaining to the conduct of 
this trial must be retained by the investigator for 15 years after end of trial unless local 
regulations or institutional policies require a lo nger retention period. No records may be 
destroyed during the retention period without th e written approval of Novo Nordisk. No records 
may be transferred to another location or party without written notification to Novo Nordisk.  
 The investigator must be able to access his/her trial documents without involving Novo Nordisk 
in any way. If applicable, electronic CRF (eCRF) and other subject data will be provided in an 
electronic readable format to the investigator before access is revoked to the systems supplied 
by Novo Nordisk. Site-specific CRFs and other subject data (in an electronic readable format or 
as paper copies or prints) must be retained by th e site. A copy of all data will be stored by Novo 
Nordisk. 
 (B/720AN@:2160.9?20<?1@:B@A/282=A3<?A52:.E6:B:=2?6<1= 2?:6AA21/FA525<@=6A.9
institution or private practice. 
Canada: for country-specific requireme nts, please see Appendix 8 (Section 10.8). 
10.1.11  Trial and site closure 
Novo Nordisk reserves the right to close the site or terminate the trial at any time for any reason at 
the sole discretion of Novo Nordisk. If the trial is suspended or terminated, the investigator must 
inform the subjects promptly and ensure appropriate therapy and follow-up. The investigator and/or 
Novo Nordisk must also promptly inform the regulatory authorities and IRBs/IECs and provide a 
detailed written explanation. 
Sites will be closed upon trial completion. A site is considered closed when all required documents 
and trial supplies have been collected and a site closure visit has been performed. 
The investigator may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a site by Novo Nordisk or investigator may include but are not 
limited to: 
 failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local 
health authorities, Novo Nordisk procedures or GCP guidelines 
 inadequate recruitment of subjects by the investigator CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 61 of 93 
 
 discontinuation of further trial product development. 
10.1.12  Responsibilities 
The investigator is accountable for the conduct of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the site. If any tasks are delegated, the investigator must 
maintain a log of appropriately qualified persons to  whom he/she has delegated specified trial-
related duties. The investigator must ensure that th ere is adequate and documented training for all 
@A.33=.?A606=.A6;46;A520<;1B0A<3A52A?6.9 A6@A526;C2 @A64.A<?N@?2@=<;@6/696AFA<@B=2?C6@2A52
conduct of the trial and to protect the rights, safety, and well-being of the subjects.  
A qualified physician, who is an investigator or a sub investigator for the trial, must be responsible 
for all trial-related medical decisions.  
The investigator is responsible for filing e ssential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. Th e documents, including the subject identification 
code list must be kept in a secure locked faci lity so that no unauthorized persons can get access to 
the data.  
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deteriora tion of data. The investigator will prevent any 
unauthorised access to data or any other processing  of data against applicable law. This also 
includes ensuring that no indirect sharing of user credentials for IT systems used in this study takes 
place (e.g., by not sharing IT equipment with others in a way where user credentials have the 
possibility of being shared). The investigator must be able to provide the necessary information or 
otherwise demonstrate to Novo Nordisk that such technical and organisational safety measures have 
been taken. 
During any period of unavailability, the investigat or must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time. 
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.  
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s). 
10.1.13  Indemnity statement  
Novo Nordisk carries product liability for its prod ucts, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.  
Novo Nordisk assumes no liability in the event of negligence or any other liability of the sites or 
investigators conducting the trial or by persons for whom the said site or investigator are 
responsible.  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 62 of 93 
 
10.1.14  Publication policy 
The information obtained during the conduct of this trial is considered confidential and may be used 
by or on behalf of Novo Nordisk for regulatory purposes as well as for the general development of 
the trial product. All information supplied by Novo Nordisk in connection with this trial shall 
remain the sole property of Novo Nordisk and is to be considered confidential information. 
No confidential information shall be disclosed to others without prior written consent from Novo 
Nordisk. Such information shall not be used except in the performance of this trial. 
The information obtained during this trial may be made available to other investigators who are 
conducting other clinical trials with the trial product, if deemed necessary by Novo Nordisk. 
Provided that certain conditions are fulfilled, Novo Nordisk may grant access to information 
obtained during this trial to researchers who require  access for research projects studying the same 
disease and/or trial product studied in this trial. 
Novo Nordisk may publish on its clinical trials website a redacted CTR for this trial. 
One (or two) investigator(s) will be appointed  by Novo Nordisk to review and sign the CTR 
(signatory investigator) on behalf  of all participating investigators. The signatory investigator(s) 
will be appointed based upon the criteria define d by the International Committee of Medical Journal 
Editors for research publications.20 
10.1.14.1  Communication of results 
Novo Nordisk commits to communicate and disclo se results of trials regardless of outcome. 
Disclosure includes publication of a manuscript in  a peer-reviewed scientific journal, abstract 
submission with a poster or oral presentation at a scientific meeting or disclosure by other means.  
The results of this trial will be subject to public  disclosure on external web sites according to 
international and national regulations. Novo Nordisk reserves the right to defer the release of data 
until specified milestones are reached, for example when the CTR is available. This includes the 
right not to release the results of interim anal yses, because the release of such information may 
influence the results of the entire trial. 
At the end of the trial, one or more scientific publ ications may be prepared collaboratively by the 
investigator(s) and Novo Nordisk. Novo Nordisk re serves the right to postpone publication and/or 
communication for up to 60 days to protect intellectual property. 
In all cases, the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. In the event of any disagreement on the 
0<;A2;A<3.;F=B/960.A6<;/<A5A 526;C2@A64.A<?@N.;1%<C<%< ?16@8<=6;6<;@D699/23 airly and 
sufficiently represented in the publication. 
10.1.14.2  Authorship 
Novo Nordisk will work with one or more investig ators and other experts who have contributed to 
the trial concept or design, acquisition, analysis or in terpretation of data to report the results in one 
or more publications. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 63 of 93 
 
Authorship of publications should be in acc ordance with the Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly  Work in Medical Journals by the International 
Committee of Medical Journal Editors.20 
All authors will be provided with the relevant st atistical tables, figures, and reports needed to 
evaluate the planned publication.  
Where required by the journal, the investigator from each site will be named in an 
acknowledgement or in the supplementary ma terial, as specified by the journal.  
10.1.14.3  Site-specific publication(s) by investigator(s) 
For a multicentre clinical trial, analyses based on si ngle-site data usually have  significant statistical 
limitations and frequently do not provide meaningful  information for healthcare professionals or 
subjects, and therefore may not be supported by Novo Nordisk. Thus, Novo Nordisk may deny a 
request or ask for deferment of the publication of individual site results until the primary manuscript 
is accepted for publication. In line with Good P ublication Practice, such individual reports should 
not precede the primary manuscript and should always  reference the primary manuscript of the trial. 
10.1.14.4  Investigator access to data and review of results 
As owner of the trial database, Novo Nordisk has th e discretion to determine who will have access 
to the database.  
Individual investigators will have  their own research subjects' da ta and will be provided with the 
randomisation code after results are available. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 64 of 93 
 
10.2 Appendix 2: Clinical laboratory tests 
 The tests detailed in Table 10-1  and Table 10-2  will be performed by the central laboratory, 
unless otherwise specified. 
 Additional tests may be performed at any time dur ing the trial as determined necessary by the 
investigator or required by local regulations. Only laboratory samples specified in the protocol should be sent to the central laboratory for analys is; if additional laboratory sampling is needed, 
e.g. to follow up on AEs, this must be done at a local laboratory. 
 The central laboratory will communicate to the investigator abnormal values of parameters not 
requested in the protocol but identified by the laboratory equipment and/or their processes 
according to their lab SOPs. These data will not be transferred to the trial database. The 
investigator should review such values for AEs and report these according to this protocol. 
 The investigator must review all laboratory results for concomitant illnesses and AEs. 
 Laboratory samples will be destroyed no lat er than at finalisation of the CTR.  
 For haematology samples (differential count) where the test result is not normal, then a part of 
the sample may be kept for up to two years or according to local regulations.  
Table 10-1 Protocol-required efficacy laboratory assessments 
Laboratory 
assessments Parameters Visit 
Glucose 
metabolism   Fasting plasma glucose1 V2, V5, V7, V10, V14, V16 
 HbA 1c V1, V2, V3, V4, V5, V7, V9, V10, V11, V12, 
V13, V14, V15, V16 
Lipids  High density lipoprotein (HDL) cholesterol 
 Low density lipoprotein (LDL) cholesterol 
 Triglycerides 
 Total cholesterol V2, V10, V14, V16 
Urinanalysis2  Urinary albumin to creatinine ratio (UACR) V2, V5, V10, V14, V16 
NOTES: 
1An FPG result H3.9 mmol/L (70 mg/dL) in relation to planned fasting visits should not be reported as a 
hypoglycaemic episode but as an AE at the discr etion of the investigator (see Appendix 3 (Section 10.3). 
2 Subjects should collect a first morning urine sample both on the day prior to the visit and on the day of the visit. 
Samples should be stored in the fridge at home and brought to the site 
Table 10-2 Protocol-required safety laboratory assessments CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 65 of 93 
 
Laboratory 
assessments Parameters Visit 
Haematology  Eosinophils 
 Lymphocytes 
 Basophils 
 Monocytes 
 Neutrophils 
 Erythrocytes 
 Haematocrit 
 Haemoglobin 
 Leucocytes 
 Thrombocytes V1, V10, V14, V16 
Biochemistry1  Alanine Aminotransferase (ALT)  
 Alkaline phosphatase 
 Aspartate Aminotransferase (AST) 
 Creatinine 
 Potassium 
 Sodium 
 Amylase 
 Lipase 
 Total bilirubin V1, V10, V14, V16 
Hormones  Calcitonin2 V2 
Pregnancy 
Testing   Urine human chorionic gonadotropin (hCG) 
pregnancy test (as needed for women of 
childbearing potential)3 V1, V16, V17 
Pharmacokinetics  Semaglutide plasma concentration V3, V5, V7, V10, V14, V16 
Antibodies  Anti-semaglutide antibodies V2, V3, V5, V7, V10, V14, V16, V17 
Other tests  eGFR calculated by the central laboratory 
based on the creatinine value using the 
CKD-EPI equation V1, V10, V14, V16 
Notes: 
1 Details of required actions and follow-up asse ssments for increased liv er parameters including any discontinuation 
criteria are given in Appendix  3 (Section 10.3) (HyNs Law) and Section 7.1. 
2 Calcitonin will be measured once at baseline. Not intended for screening. The investigator must evaluate need for 
further measurements during the trial.  
3 Local urine testing will be standard unless serum test ing is required by local regulation or IRB/IEC. 
All trial-required laboratory assessments will be  performed by a central laboratory, with the 
exception of:  
 urine pregnancy testing, which will be performed locally at site or at home 
 semaglutide plasma concentrations, which will  be performed at a specialised laboratory  
 anti-semaglutide antibodies (if deemed necessary  for clarification of unexpected drug exposure 
or other safety issues that may be related to antibody formation), which will be performed at a specialised laboratory  
Laboratory/analyte results that could unblind the trial will not be reported to the sites until the trial 
has been unblinded.CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 66 of 93 
 
10.3 Appendix 3: Adverse events: Definitions an d procedures for re cording, evaluation, 
follow-up, and reporting 
10.3.1  Definition of AE 
AE definition 
An AE is any untoward medical occurrence in a cl inical trial subject that is temporally associated 
with the use of an investigational medicinal product (IMP), whether or not considered related to 
the IMP.  
An AE can therefore be any unfavourable and unintended sign, including an abnormal laboratory 
finding, symptom or disease (new or exacerbated) temporally associated with the use of an IMP. 
 
Events meeting the AE definition 
 Any abnormal laboratory test results or safety assessments considered clinically significant in 
the medical and scientific judgment of the investigator, including events that have worsened 
from prior to the time point from which AEs are collected 
 Conditions detected or diagnosed after IMP ad ministration even though it may have been 
present prior to the time point from which AEs are collected  
 Exacerbation/worsening of a chronic or intermittent condition including either an increase in 
frequency and/or intensity of the condition 
 Signs, symptoms or the clinical sequelae of a suspected drug-drug interaction 
 Signs, symptoms or the clinical sequelae of a suspected overdose of IMP regardless of intent 
A "lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as 
an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, 
symptoms and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition. 
Events NOT meeting the AE definition  
 Conditions present prior to the time point from wh ich AEs are collected and anticipated day-to-
day fluctuations of these conditions, including those identified during screening or other trial 
procedures performed before exposure to IMP.  
 Note: Conditions present or occurring prior to the time point from which AEs are collected 
should be recorded as concomitant illness/medical history. 
 Medical or surgical procedures (e.g. endoscopy, appendectomy). The condition that leads to the 
procedure is the AE. 
 Medical or surgical procedures not preceded by an AE or worsening of a known condition. 
10.3.2  Definition of an SAE 
An SAE is an AE that fulfils at least one of the following criteria: 
a. Results in death 
b. Is life-threatening 
The term 'life -threatening' in the definition of 'serious' refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death, if it were more severe. 
c. Requires inpatient hospitalisation or pr olongation of existing hospitalisation 
 Hospitalisation signifies that the subject has be en detained at the hospital or emergency ward 
3<?</@2?C.A6<;.;1	<?A?2.A:2;AA5.AD<B91;<A5.C2/22;.==?< =?6.A26;A52=5F@606.;N@<33602CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 67 of 93 
 
or outpatient setting. Complications that occur during hospitalisation are AEs. If a complication 
prolongs hospitalisation or fulfils any other seriousness criteria, the event is serious. When in 1<B/A.@A<D52A52?K5<@=6A.96@. A6<;L<00B??21<?D.@;202@@.?F A52@5<B91/20<;@612?21
serious. 
 Hospitalisation for elective treatment (e.g. elective medical or surgical procedures) of a 
condition that was present prior to the time point from which AEs are collected, and that did 
not worsen, is not considered an AE. 
Note:  
 Hospitalisations for administrative, trial related, social and convenience reasons do not 
constitute AEs and should therefore not  be reported as AEs or SAEs.  
 Hospital admissions for medical or surgical proc edures, planned before trial inclusion, are not 
considered AEs or SAEs.  
d. Results in persistent or si gnificant disability/incapacity 
 )52A2?:16@./696AF:2.;@.@ B/@A.;A6.916@?B=A6<;<3.=2?@<;N @./696AFA<0<;1B0A;<?:.99632
functions. 
 This definition is not intended to include ex perience of relatively minor medical significance, 
such as uncompli cated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma 
(e.g. sprained ankle), which may interfere with or prevent everyday life functions but do not constitute a substantial disruption. 
e. Is a congenital anomaly/birth defect 
f. Important medical event: 
 Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations. This includes important medical events that may not be immediately life-threatening or result in death or hospit
alisation but may jeopardise the subject 
or may require medical or surgical intervention to prevent one of the other outcomes listed in 
the above definition. These events should usually be considered serious and reported as SAEs 
using the important medical event criterion. 
 The following adverse events must always be reported as SAEs using the important medical 
event criterion if no other seri ousness criteria are applicable: 
 Suspicion of transmission of infectious agents via the IMP  
 Risk of liver injury defined as alanine aminotransferase (ALT) or aspartate aminotransferase 
(AST) >3 x ULN (upper limit of normal) and total bilirubin >2 x ULN where no alternative 
aetiology exists (Hy's law) 
10.3.3  Description of AEs requiring additional data collection  
Description of AEs requiring additional d ata collection (on specific event form)  
Adverse events requiring additional data collection  
AEs requiring additional data collection ( Table 8-1) are AEs where the additional data will benefit 
the evaluation of the safety of the trail product. The selection of these events is based on the non-
clinical and clinical data with semaglutide , knowledge from the GLP- 1 RA drug class as well as 
regulatory requirements.  
Diabetic retinopathy  
New onset or worsening of diabetic retinopathy.  
Gallbladder disease  
Events of symptomatic gallbladder disease, including gallstones and cholecystitis.  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 68 of 93 
 
Hepatic event 
Hepatic event defined as:  
 disorders of the liver including cholestatic c onditions and liver related signs and symptoms 
 ALT or AST > 3x ULN and total bilirubin > 2x ULN* 
 ALT or AST > 3x ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, feve r, rash, and/or eosinophilia (>5%) 
&92.@2;<A2A5.A6;0.@2<3@B05.52=.A602C2;AD52?2;<.9A 2?;.A6C2.2A6<9<4F2E6@A@FN@9.D
the event must be reported as an SAE using the important medical event criterion if n o other 
seriousness criteria are applicable.  
Neoplasms  
All c onfirmed neoplasms (both malignant and non-malignant ) by histology or other substantial 
clinical evidence.  
Acute p ancreatitis 
The diagnosis of acute pancreatitis requires two of the following three features: 
 abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, 
epigastric pain often radiating to the back). 
 serum lipase activity (and/or amylase activity) at  least three times greater than the upper limit 
of normal. 
 characteristic findings of acute pancreatitis imaging. 
Acute kidney injury 
Event of an abrupt or rapid decline in renal filtr ation function. This condition is usually marked 
by a rise in serum creatinine concentration or by azotemia (a rise in blood urea nitrogen (BUN) 
concentration).  
Medication error  
A medication error is an unintended failure in th e IMP treatment process that leads to, or has the 
potential to lead to, harm to the subject, such as:   
 administration of wrong drug 
Note: Use of wrong DUN is not considered a medication error unless it results in 
administration of wrong drug.  
 wrong route of administration 
 accidental administration of a higher dose than  intended. The administered dose must deviate 
from the intended dose to an extent where clinic al consequences for the trial subject were 
likely to happen as judged by the investigator, although they did not necessarily occur. 
Misuse and abuse  
 Situations where the IMP is intentionally and inappropriately used not in accordance with the 
protocol (e.g. overdose to maximise effect) 
 Persistent or sporadic, intentional excessive us e of an IMP which is accompanied by harmful 
physical or psychological effects (e.g. overdose with the intention to cause harm) 
Medication error, misuse and abuse must always be  reported as an AE (e.g. accidental overdose, 
intentional overdose or other) on a separate AE form, and a medication error, misuse and abuse 
form must be completed. In case of a medication error and/or misuse and abuse resulting in a 
clinical consequence (e.g. hypoglycaemia or other), this must be reported on an additional AE form. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 69 of 93 
 
10.3.4  Recording and follow-up of AE and/or SAE 
AE and SAE recording 
 The investigator will record all relevant AE/SAE information in the CRF. 
 The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE. 
 When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospital progress notes, laborat ory and diagnostics reports) related to the 
event.  
 There may be instances when copies of source documents (e.g. medical records) for certain 
cases are requested by Novo Nordisk. In su ch cases, all subject identifiers, with the exception 
of the subject number, will be redacted on the copies of the source documents before 
submission to Novo Nordisk. 
 For all non-serious AEs, the applicable forms should be signed when the event is resolved or at 
the end of the trial at the latest. For sign- <33<3(?29.A213<?:@?232?A<K.;1(
?2=<?A6;4C6.=.=2?'L9.A2?6;A56@@20A6<;  
 Novo Nordisk products used as concomitant medication: if an AE is considered to have a 
causal relationship wi th a Novo Nordisk marketed product used as concomitant medication in 
the trial, it is important that the suspected relationship is reported to Novo Nordisk, e.g. in the 
alternative aetiology section on the safety information form. Novo Nordisk may need to report 
this adverse event to relevant regulatory authorities.  
 
Assessment of severity 
The investigator will assess severity for each event reported during the trial and assign it to one of 
the following categories:   
 Mild : An event that is easily tolerated by the subject, causing minimal discomfort and not 
interfering with everyday activities. 
 Moderate : An event that causes sufficient discomfort and interferes with normal everyday 
activities. 
 Severe : An event that prevents normal everyday activities.  
Note: An AE that is assessed as severe should not be confused with a SAE. Both AEs and 
SAEs can be assessed as severe.  
 
Assessment of causality 
 The investigator is obligated to assess the relationship between IMP and the occurrence of each 
AE/SAE. 
 Relationship between an AE/SAE and the relevant IMP(s) should be assessed as:   Probable - Good reason and sufficient documentation to assume a causal relationship. 
 Possible - A causal relationship is conceivable and cannot be dismissed. 
 Unlikely - The event is most likely related to aetiology other than the IMP. 

 Alternative aetiology, such as underlying disease(s), concomitant medication, and other risk 
factors, as well as the temporal relationship of the event to IMP administration, will be 
considered and investigated. 
 )526;C2@A64.A<?@5<B91B@2A526;C2@A64.A<?N@/?<05B?2 for the assessment. For each AE/SAE, 
the investigator must document in the medical records that he/she has reviewed the AE/SAE 
and has provided an assessment of causality. 
 There may be situations in which an SAE ha s occurred, and the investigator has minimal 
information to include in the initial report. However, it is important that the investigator CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 70 of 93 
 
always makes an assessment of causality for ev ery event before the initial transmission of 
the SAE data.  
 The investigator may change his/her opinion of causality, in light of follow- up information, 
and update the causality assessment in the CRF. 
 The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. 
Final outcome 
The investigator will select the most appropriate outcome: 
 Recovered/resolved:  The subject has fully recovered, or by medical or surgical treatment the 
condition has returned to the leve l observed when first documented 
 Recovering/resolving:  The condition is improving, and the subject is expected to recover from 
the event. This term may be applicable in ca ses of chronic conditions, cancer or AEs ongoing 
at time of death (where death is due to another AE).  
 Note: For SAEs, this term is only applicable if the subject has completed the follow- up period 
and is expected to recover. 
 Recovered/resolved with sequelae:  The subject has recovered from the condition but with 
lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE 
criterion, the AE must be reported as an SAE. 
 Not recovered/not resolved:  The condition of the subject has not improved, and the symptoms 
are unchanged, or the outcome is not known.  
Note: This term may be applicable in cases of chronic conditions, cancer or AEs ongoing at 
time of death (where death is due to another AE).  
 Fatal:  This term is only applicable if th e subject died from a condition related to the reported 
AE. Outcomes of other reported AEs in a subj ect before he/she died should be assessed as 
K?20<C2?21	?2@<9C21LK?20<C2?6;4	?2@<9C6;4LK?20<C2?21	?2@<9C 21D6A5@2>B29.2L<?K;<A
recovered/not resolved L;D6A5.3.A.9<BA0<:2:B@A/2?2=<?A21.@.;(  
 Unknown:  This term is only applicable if the subject is lost to follow-up. 
 
Follow-up of AE and SAE 
The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by Novo Nordisk to elucidate the nature and/or causality of the AE or SAE as fully as possible (e.g. severe hypersensitivity reactions). This may include additional laboratory tests (e.g. skin pric
k test) or investigations, 
histopathological examinations, or consultation with other health care professionals.  
If a subject die s during participation in the trial or during a recognised follow-up period, the 
investigator should provide Novo Nordisk with a copy of autopsy report including 
histopathology, if available.  
New or updated information will be recorded in the CRF. 
10.3.5  Reporting of SAEs 
SAE reporting via electronic CRF 
 Relevant forms (AE and safety information fo rm) must be completed in the eCRF.  
 For reporting and sign-off timelines, see Figure 10-1  below.  
 If the CRF is unavailable for more than 24 hours, then the site will use the paper AE form, and 
if the CRF is unavailable for more than 5 calendar days, then the site will use the safety 
information form (see box below). CONFIDENTIAL
Protocol
CONFIDENTIALDate: 16 September 2022 Novo Nordisk
Trial ID: NN9924-4635 Version: 7.0
     Status: Final
     Page: 71 of 93
The site will enter the SAE data into the eCRF as soon as it becomes available.
After the trial is completed, the trial databas e will be locked, and the CRF will be 
decommissioned to prevent the entry of new data or chan ges to existing data. If a site receives 
a report of a new SAE from a subject or receives updated data on a previously reported SAE after CRF decommission, then the site can report this information on a paper AE and safety information form (see box below)  or to Novo Nordisk by telephone.
AE and SAE reporting via paper CRF
Relevant CRF forms (AE and safety information form) must be forwarded to Novo Nordisk in 
an encrypted manner in accordance with Section 10.1.5 .
For SAEs, initial notification via telephone is ac ceptable, although it does not replace the need 
for the investigator to complete the AE and safety information form within the designated 
reporting timelines (as illustrated in the figure below):
AE form within 24 hours
Safety information form within 5 calendar days
Both forms must be signed within 7 calendar days after first knowledge by the investigator.
The specific event form for AEs requiring additional data collection within 14 calendar days
AE identifiedAE formâ¤  24 hours
SIF â¤5 calendar days
Sign offâ¤ 7 calendar days
Is the AE serious , or
non-serious?
Does the AE require 
additional data 
collection?
Non-seriousSe rious
NoSpecific event form
For SAE : 
â¤14 calendar days
Yes
 Timelines are from the awareness of an AE.
 Queries and follow-up requests to be resolved â¤14 calendar days.
 Non-serious AEs: Data must be recorded in the CRF as soon as possible, 
preferably within 5 working days (see Appendix 1)
AE: Adverse Events, SAE: Serious Adverse Events, SIF: Safety Information FormAE Form
No additional 
action
NOTE: The collection of AEs includes the collectio n of COVID-19 or suspected COVID-19 AEs.
Figure 10-1 Decision tree fo r determining the event type and the respective forms to
complete with associated timelines
Contact details for SAE reporting can be found  in the investigator trial master file.CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 72 of 93 
 
10.4 Appendix 4: Contraceptive guidance and co llection of pregnancy information 
Definitions 
Woman of childbearing potential (WOCBP) 
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile.  
If fertility is unclear (e.g. amenorrhea in adoles cents or athletes), and a menstrual cycle cannot be 
confirmed before first dose of trial treatment, additional evaluation should be considered. 
Females in the following categories are not considered WOCBP 
1. Premenarcheal 
2. Females with one or more of the following: 
 Documented total hysterectomy 
 Documented bilateral salpingectomy 
 Documented bilateral oophorectomy 
Females with permanent infertility due to an alte rnate medical cause other than the above (e.g. 
MÃ¼llerian agenesis, androgen insensitivity), invest igator discretion should be applied in determining 
trial enrolment. 
3. Postmenopausal female: 
 A postmenopausal state is defined as amenorrhoea  for 12 months without an alternative medical 
cause.  
 Females I
F2.?@<3.420.;/20<;@612?21=<@A:2;<=.B@.96??2@=20A6C 2<3A?2.A:2;AD6A5.
hormonal contraception or hormone replacement therapy (HRT)) if they have both: 
 Amenorrhoea and 
 Documentation of 2 high follicle stimulating hormone (FSH) measurements in the 
=<@A:2;<=.B@.9?.;42.;1<;2<3A52@2D.@</@2?C21IF2.?=?6< ?A<@0?22;6;4  
 2:.92@I
F2.?@<3.420.;/20<;@612?21=<@A:2;<=.B@.9  
Females on HRT and whose menopausal status is in doubt are considered of childbearing potential 
and will be required to use one of the highly effective contraception methods.  
Note: Documentation regarding categories 1- 
0.;0<:23?<:A52@6A2@A.33N@?2C62D<3@B/720AN@
medical records, medical examination or medical history interview. 
Contraception guidance 
Male subjects  
No contraception measures are required for male subjects, because the risk of 
teratogenicity/fetotoxicity caused by transfer of semaglutide in seminal fluid is unlikely. 
Female subjects 
Female subjects of childbearing potential are eligible to participate if they agree to use methods of 
contraception consistently and correct ly as described in table below: CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 73 of 93 
 
Table 10-3 Highly effective contraceptive methods  
CONTRACEPTIVES a ALLOWED DURING THE TRIAL INCLUDE: 
 Highly effective methods b, d that have low user dependency  (Failure rate of <1% per year 
when used consistently and correctly): 
 Implantable progestogen- only hormone contraception associated with inhibition of ovulationb 
 Intrauterine device (IUD) 
 Intrauterine hormone-releasing system (IUS)b 
 Bilateral tubal occlusion 
 Vasectomized partner 
(Vasectomized partner is a highly effective contraceptive method provided that the partner is 
the sole sexual partner of the woman of childbearing potential, and the absence of sperm has 
been confirmed. If not, an additional highly effective method of contraception should be used. 
Spermatogenesis cycle is approximately 90 days.) 
 
 Highly effective methods b,d that are user dependent  (Failure rate of <1% per year when used 
consistently and correctly):  
 Combined (estrogen- and progestogen-containing) hormonal contraception associated with 
inhibition of ovulation c 
o oral 
o intravaginal 
o transdermal 
o injectable 
 Sexual abstinence 
(Sexual abstinence is considered a highly effe ctive method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the trial treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the subject.) 
NOTES 
a) Contraceptive use by men or women s hould be consistent with local regulations regarding the 
use of contraceptive methods for those participating in clinical trials. 
b) Failure rate of <1% per year when used consistently and correctly. Typical use failure rates 
differ from those when used consistently and correctly. 
c) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines,  
contraceptive methods are limited to those which inhibit ovulation as the primary mode of 
action. 
d) Contraception should be utilised during the treatment period and for at least 35 days 
(corresponding to time needed to eliminate trial product) after the last dose of trial treatment. 
In certain cases, it is accepted to use double barrier methods (a condom combined with an occlusive 
cap (e.g. diaphragm) with/without the use of spermi cide). This should only be allowed in females 
with: 
1. known intolerance to the highly effective methods mentioned in Table 10-3  or where the use of 
any of the listed highly effective contraceptive  measures are contraindicated in the individual 
subject, and/or 
2. if the risk of initiating treatment with a specific highly effective method outweighs the benefit 
for the female. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 74 of 93 
 
Justification for accepting double barrier method s hould be at the discretion of the investigator, 
A.86;46;A<0<;@612?.A6<;56@	52?8;<D92142./<BAA5232:.92N@ :2160.956@A<?F0<;0<:6A.;A699;2@@
concomitant medication and observed AEs. The justif ication must be stated in the medical records. 
Czech Republic, and Germany: For country-specif ic requirements, please see Appendix 8 (Section 
10.8). 
Pregnancy testing 
 WOCBP should only be included after a negative high ly sensitive urine pregnancy test (refer to 
Appendix 2, Section 10.2) 
 Additional pregnancy testing should be per formed according to the flowchart (Section 1.2). 
 Pregnancy testing should be performed whenever  a menstruation is missed or when pregnancy 
is otherwise suspected. 
 Pregnancy testing is advised 5 weeks after premature discontinuation of trial treatment. 
 Additional pregnancy testing should be perfor med during the treatment period, if required 
locally (Appendix 8, Section 10.8). 
Collection of pregnancy information  
Female subjects who become pregnant  
 Investigator will collect pregnancy information on any female subject who becomes pregnant 
while participating in this trial. 
 Information will be recorded on the appropriate form and submitted to Novo Nordisk within 14 
calendar days of learning of a subject's pregnancy (see Figure 10-2 ). 
 Subject will be followed to determine the outcome of the pregnancy. The investigator will 
collect follow-up information on subject and neona te which will be forwarded to Novo Nordisk 
within 14 calendar days. Generally, follow-up will not be required for longer than 1 month 
beyond the delivery date. 
 Any termination of pregnancy will be reporte d, regardless of foetal status (presence or absence 
of anomalies) or indication for procedure. 
 While pregnancy itself is not considered to be an AE or SAE, any adverse event in connection 
with pregnancy or elective termina tion of a pregnancy for medical reasons will be reported as an 
<?( 3?292C.;A0<;@612?.116;4M42@A.A6<;.9NM=?24;.; 0F?29.A21N<?.@6:69.?A2?:
when reporting the AE/SAE. 
 Pregnancy outcome should be documented in the subject's medical record. Abnormal pregnancy 
outcome (e.g. spontaneous abortion, foetal death, st illbirth, congenital anomalies and ectopic 
pregnancy) is considered an SAE. 
 Any SAE occurring as a result of a post-trial pregnancy which is considered possibly/probably 
related to the IMP by the investigator will be reported to Novo Nordisk as described in 
Section 10.3. While the investigator is not obligated to actively seek this information in former 
subjects, he or she may learn of an SAE through spontaneous reporting. 
 CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 75 of 93 
 
Maternal form 1b  
â¤ 14 calendar days after birthMaternal form 1a
â¤ 14 calendar daysAfter birth/
termination 
of pregnancy
No additional 
action Normal outcome Maternal f orm 2 â¤ 14 calendar days
Paternal form*1 â¤ 14 calendar days Abnormal outcome 
Pregnancy 
verified
*1 Further information collected on Paternal form for male partners of 
female subjects requires signing of specific informed consent.
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Figure 10.1.Prior to 
birth or 
pregnancy 
termination For female subjects
 
Figure 10-2 Decision tree fo r determining the forms to complet e with associated timelines 
for pregnancy.  
Any female subject who becomes pregnant while pa rticipating in the trial will discontinue IMP.  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 76 of 93 
 
10.5 Appendix 5: Technical complaints: Defini tion and procedures for recording, 
evaluation, follow-up and reporting 
10.5.1  Definition of technical complaint 
Technical complaint definition  
 A technical complaint  is any written, electronic or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE but does not concern the AE itself. 
Examples of technical complaints: 
 Problems with the physical or chemical appearan ce of trial products (e.g. discoloration, particles 
or contamination) 
 Problems with packaging material including labelling  
Time period for detecting technical complaints  
All technical complaints  which occur from the time of receip t of the product at site until the time 
of the last usage of the product must be collec ted for products predefined on the technical 
complaint form.  
10.5.2  Recording and follow-up of technical complaints 
Reporting of technical complaints to Novo Nordisk 
Contact details for Customer Compl aint Center, please refer to Attachment I . 
Technical complaints must be reported on a separate technical complaint form:  
1. One technical complaint form must be completed for each affected DUN. 
2. If DUN is not available, a technical complaint form for each batch, code or lot number must 
be completed. 
 
Timelines for reporting of technical complaints to Novo Nordisk 
The investigator must complete the technical complaint form in the CRF within: 
 24 hours if related to an SAE (or could have led to an SAE) 
 5 days calendar for all other technical complaints  
If the CRF is unavailable, or when reporting a technical complaint on a trial product that is not 
yet allocated to subject , the  information must be provided on a paper form to Customer 
Complaint Center, Novo Nordisk, within the sa me timelines as stated above. When the CRF 
becomes available again, the investigator must enter the information on the technical complaint form in the CRF.  
 
Follow-up of technical complaints  
The investigator is responsible for ensuring th at new or updated information will be recorded on 
the originally completed form.  
 CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 77 of 93 
 
Collection, storage and shipment of technical complaint samples 
The investigator must collect the technical complaint sample and all associated parts that were 
packed in the same DUN and notify the monitor within 5 calendar days of obtaining the sample at site. The sample and all associated parts must be sent as soon as possible to Customer Complaint Center, Novo Nordisk, together with a copy of the completed technical complaint form. The technical complaint sample should contain the batc h, code or lot number and, if available, the 
DUN. If the technical complaint sample is unobtainable,
 the reason must be stated on the 
technical complaint form. If several samples are shipped in one shipment, the sample and the 
corresponding technical complaint form should be kept together.  
Storage of the technical complain t sample must be done in accorda nce with the conditions 
prescribed for the product.  
10.5.3  Reporting of technical complaints 
Reporting of technical complaints for Novo No rdisk products not included in technical 
complaint form 
Technical complaints on Novo Nordisk products not included in the technical complaint form 
should be reported to local Novo Nordisk. 
 CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 78 of 93 
 
10.6 Appendix 6: Hypoglycaemic episodes 
Table 10-4 Classification of hypoglycaemia 
Classification of hypoglycaemia 
Level Glycaemic criteria Description 
Hypoglycaemia alert value 
(level 1)  H 3.9 mmol/L (70 mg/dL) and  
I

::<9	#:4	1#  Sufficiently low for treatment with fast-acting 
carbohydrate and dose adjustment of glucose -lowering 
therapy 
Clinically significant 
hypoglycaemia (level 2) < 3.0 mmol/L (54 mg/dL) Sufficiently low to indicate serious, clinically 
important hypoglycaemia 
Severe hypoglycaemia 
(level 3) No specific glucose threshold 1Hypoglycaemia associated with severe cognitive 
impairment requiring external assistance for recovery 
Notes: The Novo Nordisk terms are adapted from IHSG21, ADA22, ISPAD23, type 1 diabetes outcomes program24, 
ATTD25. Severe hypoglycaemia as defined by Seaquist26 and ISPAD23. 
Severe hypoglycaemia 
1Severe hypoglycaemia is an event requiring assi stance of another person to actively administer 
carbohydrates, glucagon, or take other corrective acti ons. Plasma glucose concentrations may not be 
available during an event, but neurological recovery following the return of plasma glucose to 
normal is considered sufficient evidence that the event was induced by a low plasma glucose 
concentration.26 
Nocturnal hypoglycaemia 
Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05:59 both inclusive. 
Reporting of hypoglycaemic episodes 
Reporting of hypoglycaemic episodes by BG meters:  
Plasma glucose (PG) should always be recorded in the diary/eCRF when a hypoglycaemic episode 
is suspected.  
Hypoglycaemic episodes should be reported accord ing to the instructions below. When a subject 
experiences a hypoglycaemic episode, the subjec t should record the general information in relation 
to the hypoglycaemia (timing, PG measurements, symptoms etc.) as described in the diary. The investigator should ensure correct reporting of the hypoglycaemic episode and report the 
hypoglycaemic episode to the eCRF. In case a subject is not able to fill in the diary (e.g. in case of 
hospitalisation), the investigator should still report the hypoglycaemic episode on the 
hypoglycaemic episodes form in the eCRF.  
If the hypoglycaemic episode fulfils the criteria for an SAE, then in addition to the above, an AE 
form and a safety information form must also be filled in. One AE form and safety information 
form can cover several hypoglycaemic episode forms,  if the subject has not recovered between the 
episodes. 
Upon onset of a hypoglycaemic episode the subject is recommended to measure PG every 
15 minutes until the PG value is >3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved in 
accordance with current guidelines.
26 CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 79 of 93 
 
Repeated PG measurements and/or symptoms will by default be considered as one hypoglycaemic 
episode until a succeeding PG value is >3.9 mmol/L (70 mg/dL) and/or symptoms have been 
resolved and should be reported as only one hypoglycaemic episode. In case of several low PG 
values within the hypoglycaemic episode, the lowest value is the one that will be reported as the PG 
value for the hypoglycaemic episode, but the start ti me of the episode will remain as the time for the 
first low PG value and/or symptom. The remaining values will be kept as source data. 
If the severity of a hypoglycaemic episode changes, only one hypoglycaemic episode will be 
reported, reflecting the most severe degree of hypoglycaemia. 
'24.?16;4A52>B2@A6<;K)<3229/2AA2?161F<B;221529=A<4 2A.@B4.?F1?6;83<<1<?
:21606;2LA526;C2@A64.A<?:B@A6;@A?B0AA52@B/720A@A<.;@D2 ?K-2@L63A522=6@<12D.@.; event 
that required assistance of another person to act ively administer carbohydrate, glucagon, or take 
other corrective actions. PG concentrations may no t be available during an event, but neurological 
recovery following the return of PG to normal is considered sufficient evidence that the event was 
induced by a low PG concentration.26 
Additional information (e.g. description of symptoms , alleviation of symptoms, seizure or coma) in 
relation to severe hypoglycaemic episodes must be recorded in the hypoglycaemic episode eCRF.  
Diary review 
At each contact the investigator must review the diary data for correct reporting of PG values and 
hypoglycaemic episodes. In case of incomplete or incorrect data in the diary, the subject must be 
questioned whether there have been any severe hypoglycaemic episodes since the last visit and 
report accordingly. 
For low PG values for hypoglycaemic episodes with incomplete reporting information:  
 If a hypoglycaemic episode form in the diary is not completed by the subject within 7 calendar 
days of the PG measurement, the episode should be described in the source documents and 
reported by the investigator on a hypoglycaemic episode (e)CRF with as much information as 
possible. If the subject did not need help to get a sugary drink, food, or medicine, Novo Nordisk 
will only ask for start date due to recall bias.27, 28 
Re-training of subjects 
The subject must be re-trained in how to report hypog lycaemic episodes if the investigator identifies 
low PG values not reported as hypoglycaemic episodes. The training should be documented by the 
investigator in source documents.  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 80 of 93 
 
10.7 Appendix 7: Retention of human biosamples 
Remaining and residual antibody samples already collected (Sections 8.5 and 8.9) may be retained 
after end of the trial. 
 The samples will be stored at Novo Nordisk or a biorepository assigned by Novo Nordisk after 
end of trial and until marketing authorisation a pproval or until the research project terminates, 
but no longer than 15 years from the end of th e trial after which they will be destroyed. 
 Samples might be transferred to other countri es, to a laboratory assigned by Novo Nordisk. 
 The retained samples may be used to: 
 evaluate safety or efficacy aspects that address concerns arising during or after the trial. 
 further characterise the antibody responses towards the drug, if required by health authorities or 
for safety reasons. 
 conduct further analytical method developm ent and validation of antibody assays. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 81 of 93 
 
10.8 Appendix 8: Country-specific requirements  
Section 5.1 Inclusion criteria 
For Taiwan: 
Inclusion criteria 2: I
 years at the time of signing informed consent. 
Section 5.2 Exclusion criteria 
For Croatia and Germany: 
Exclusion criterion 15: K*Simultaneous participation in a tr ial with the primary objective of 
evaluating an approved or non-approved invest igational medicinal product for prevention or 
treatment of COVID 19 disease or COVID-19 postinfectious conditions is allowed if the last dose 
of the investigational medicinal product has been received more than 30 days before screening. Lis 
not applicable for Croatia and Germany. 
Section 6.5 Concomitant medication 
For Croatia and Germany: 
KMedication administered in relation to a clinica l trial for COVID-19 prevention or treatment L6@
not applicable for Croatia and Germany. 
Section 7.1 Discontinuation of trial treatment 
For Croatia and Germany: 
6@0<;A6;B.A6<;<3A?6.9A?2.A:2;A0?6A2?6<;K *Simultaneous participation in a trial with the 
primary objective of evaluating an approved or non-approved investigatio nal medicinal product for 
prevention or treatment of COVID-19 disease or CO VID-19 postinfectious conditions is allowed at 
the investigator discretion without discontinuing trial product. L6@;<A.==960./92  for Croatia and 
Germany. 
Section 8.2.3  Eye examination 
For Germany: 
Fundus photography have to be performed by an ophthalmologist. Performance of fundus 
photography by an optimetrist or another qualified health care provider is not allowed. 
For United States of America: 
Fundus photography will be performed by the Investigator or a local Ophthalmologist/Optometrist 
according to local practice. 
Appendix 1, Section 10.1.10  Retention of clinical trial documentation 
For Canada: 
Retention period is 25 years. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 82 of 93 
 
Appendix 4 Contraceptive guidance and collection of pregnancy information 
For Czech Republic and Germany: 
Contraceptive measures considered adequate incl ude highly effective contraceptive methods in 
.00<?1.;02D6A5A52)@K'20< ::2;1.A6<;@?29.A21A<0<;A?.02= A6<;.;1=?24;.;0FA2@A6;46;
clinical trials Las listed in Table 10-3 . CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 83 of 93 
 
10.9 Appendix 9: Abbreviations  
ADA American Diabetes Association 
AE adverse event 
ALT alanine aminotransferase 
ANCOVA analysis of covariance 
AST aspartate aminotransferase 
BG blood glucose 
BMI body mass index 
BUN blood urea nitrogen  
CFR Code of Federal Regulations  
CKD chronic kidney disease  
CKD-EPI Chronic Kidney Disease Ep idemiology Collaboration 
CRF case report form 
COVID-19 Coronavirus disease 2019 
CTFG Clinical Trial Facilitation Group 
CTR clinical trial report 
CV cardiovascular 
CVD cardiovascular disease 
DFU directions for use 
DPP-4 dipeptyl peptidase-4 
DUN dispensing unit number 
EAC event adjudication committee 
EASD European Association for the Study of Diabetes 
ECG electrocardiogram 
eCRF electronic case report form 
eGFR estimated glomerular filtration rate 
FAS full analysis set 
FDA U.S. Food and Drug Administration 
FDAAA FDA Amendments Act 
FPG fasting plasma glucose 
FSH follicle-stimulating hormone  
GCP Good Clinical Practice 
GI gastrointestinal 
GLP-1 glucagon-like peptide-1 
GLP-1 RA glucagon-like peptide-1 receptor agonist CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 84 of 93 
 
HbA 1c glycated haemoglobin 
HCG human chorionic gonadotropin  
HDL high-density lipoprotein 
HDPE High density polyurethane 
HF heart failure 
HRT hormone replacement therapy 
ICH International Council for Harmonisation 
IEC independent ethics committee 
IMP investigational medicinal product 
IRB institutional review board 
IUD Intrauterine device  
IUS Intrauterine device  
IWRS interactive web response system 
KDIGO kidney disease improving global outcomes 
LDL low-density lipoprotein 
LSFT last subject first treatment  
MAR missing at random  
MEN2 multiple endocrine neoplasia type 2  
MMRM mixed model for repeated measurement 
NYHA New York Heart Association 
OAD oral anti-diabetic drug 
OTC over-the-counter 
PCD primary completion date 
PG plasma glucose 
PK pharmacokinetic 
SAE serious adverse event 
SAP statistical analysis plan 
SAS Safety analysis set 
s.c. subcutaneous 
SGLT2 sodium-glucose co-transporter 2 
SU sulphonylurea 
SUSAR suspected unexpected se rious adverse reaction 
TD treatment difference 
T2D type 2 diabetes 
TMM trial materials manual CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 85 of 93 
 
ULN upper limit of normal 
UACR urinary albumin to creatinine ratio  
WOCBP woman of child bearing potential 
 
 CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 86 of 93 
 
10.10  Appendix 10: Protocol amendment history 
The Protocol amendment summary of changes table for the current protocol version is located 
directly before the table of contents. 
Protocol version 2.0, including protocol amendment no. 1: 09 November 2020, global 
This amendment is considered to be substantial base d on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union. 
Overall rationale for preparing protocol, version 2.0 
Due to the COVID-19 pandemic, the exclusion and discontinuation criteria have been amended to 
allow for simultaneous participation in trials with the primary objective of evaluating an approved 
or non-approved investigational medicinal produc t for prevention or treatment of COVID-19 
disease or COVID-19 postinfectious conditions. 
This amendment also addresses clarifications for misse d doses and treatment compliance, as well as 
administrative changes. 
Section # and name Description of change Brief rationale 
Section 1.2 Flowchart <?+.;1+C6@6AD6;1<D0<??20A213?<:M
N
A<MG
N  For correctness 
Section 1.2 Flowchart For V17, visit window corrected from 0/3 to +3 For correctness 
Section 1.2 Flowchart For Laboratory Assessments, added X under the 
visit columns For correctness 
Section 5.2 Exclusion 
criteria  Addition to exclusion criterion 15 
*Simultaneous participation in a trial with the 
primary objective of evaluating an approved or 
non-approved investigational medicinal product for 
prevention or treatment of COVID -19 disease or 
COVID -19 postinfectious conditions is allowed if 
the last dose of the investigational medicinal 
product has been  received more than 30 days before 
screening. To allow for co-participation in 
COVID -19 trials 
Section 6.1 Missed 
doses  Text modified with regards to guidance on missed 
doses  To clarify that if the subject has 
been off treatment for more than 10 
consecutive days, the investigator 
should consult Novo Nordisk 
global medical experts for guidance 
regarding continuation of trial 
medication.  
Section 6.4 Treatment 
compliance  Definition of treatment compliance added To clarify that compliance is 
defined as taking between 
80%-120% of the dose as 
prescribed between visits.  CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 87 of 93 
 
Section # and name Description of change Brief rationale 
Section 6.5 
Concomitant 
medication  Text included for collection of COVID-19 
concomitant medication  To specify that medication(s) in 
relation to a clinical trial for 
COVID -19 prevention o r treatment 
as well as approved COVID -19 
vaccine must be recorded.  
Section 7.1 
Discontinuation of 
trial treatment  Text added to discontinuation criterion 5 
*Simultaneous participation in a trial with the 
primary objective of evaluating an approved or 
non-approved investigational medicinal product for 
prevention or treatment of COVID -19 disease or 
COVID -19 postinfectious conditions is allowed at 
the investigator discretion without discontinuing 
trial product. To allow for co-participation in a 
COVID -19 trial 
Section 8.2 Safety 
assessments  Addition of COVID-19 in text  To include COVID-19 to the 
concomitant illness/medical history 
that should be reported in relevant 
forms 
Section 8.3 Adverse 
events  Text regarding COVID-19 AEs included 
*including AEs of COVID-19, irrespective of 
seriousness. Note: Suspected COVID -19 should be 
reported if the clinical presentation is suggestive of 
COVID -19, even in the absence of a COVID- 19 
test or without a positive COVID -19 test result. In 
the absence of clinical symptom s, a positive 
COVID -19 test (antigen or antibody) should be 
reported, if available. To describe the procedure for 
collection of COVID -19 AEs 
Appendix 2 Bilirubin removed from the list of Biochemistry test 
parameters For correctness 
Appendix 3, Figure 
10-1 Text regarding COVID-19 AEs included To describe the procedure for 
collection of COVID -19 AEs 
 
Protocol version 3.0, including protocol am endment no. 1 and 2: 04 March 2021, global 
This amendment is considered to be substantial base d on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union. 
Overall rationale for preparing protocol, version 3.0 
The exposure-response modelling has been updated ba sed on data that have become available after 
the completion of the first version of the protocol . The new predicted treatment differences for 50 
mg and 25 mg compared to 14 mg are less than previously predicted and therefore, the sample size 
has been increased to maintain the power. 
This amendment also addresses few additional change s such as third-party responsibility and user 
credentials for IT systems. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 88 of 93 
 
Section # and name Description of change Brief rationale 
Protocol amendment 
summary of changes 
table  Substantial amendment as per the 
European Parliament and the Council of 
the European Union  Reference added for information  
Section 1.1 Synopsis Number of subjects changed from 1224 
to 1620.  To ensure sufficient power given the lower 
expected treatment differences  
Section 2.3.1 Risk 
assessment  Allergic reactions and neoplasms New information added to align with the 
current risk assessment of semaglutide  
Section 2.3.1 Risk 
assessment  COVID-19 related mitigation plan To develop a COVID-19 mitigation plan for 
this trial  
Section 4.2 Scientific 
rationale for trial design Third-party responsibility  To clarify that a third-party, who is only 
allowed to be involved in trial product 
handling, will be responsible for drug 
accountability  
Section 6.3 Measures to 
minimise bias: Randomisation and 
blinding
 Blinding and trial product handling To clarify the third-party responsibilities in 
relation to trial product handling  
Section 6.3 Measures to 
minimise bias: 
Randomisation and 
blinding  Quality Assurance audit at site(s) To follow GCP advice agreement, text 
regarding Quality Assurance audit at site(s) 
and allowing them access to unblinded trial 
treatment records at the site(s) has been 
removed  
Section 8.2.4 Eye 
examination  Fundus photography or slit-lamp 
biomicroscopy  To clarify that fundus photography or slit-
lamp biomicroscopy examination should be used for evaluation of retinopathy or 
maculopathy. Additional examinations (e.g., 
optical coherence tomography and/or best 
corrected visual acuity) can be performed as 
a supplement for further evaluation. However, in this trial, additional eye 
examinations including the optical 
coherence tomography and/or best corrected 
visual acuity, cannot replace the fundus 
photography or slit
-lamp biomicroscopy 
examination  
Section 9.2 Sample size 
determination  Updated sample size assumption To ensure sufficient power given the lower 
expected treatment differences  
Section 9.4.2 Primary 
endpoint  Updated tipping point sensitivity analysis 
and added an extra sensitivity analysis To accommodate feedback from FDA 
Section 9.4.3.1 
Confirmatory 
secondary endpoint Updated with similar sensitivity analyses 
as for the primary endpoint  To accommodate feedback from FDA CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 89 of 93 
 
Section # and name Description of change Brief rationale 
Section 10.1.12 
Responsibilities  Sharing of user credentials for IT 
systems  To emphasize that the investigator will 
ensure that IT equipment will not be shared 
with others in a way where user credentials 
have the possibility of being shared  
Appendix 2 (Section 
10.2) Clinical 
laboratory tests In Table 10-1, V15 removed for fasting 
plasma glucose  For correctness 
Appendix 2 (Section 
10.2) Clinical 
laboratory tests  In Table 10-1 footnote, FPG of 
<3.9 ::<9	#05.;421A<H
  mmol/L  For correctness 
Appendix 6 (Section 
10.6) Hypoglycaemic 
episodes  In Table 10-4, Hypoglycaemia alert 
value (level 1) <3.9 mmol/L changed to 
H
 mmol/L For correctness 
Appendix 6 (Section 
10.6) Hypoglycaemic 
episodes  &C.9B2I
::<9	#05.;421A<
>3.9 mmol/L 
For repeated PG measurements, 
succeeding PG value c hanged from 
I
 mmol/L to >3.9 mmol/L For correctness 
Appendix 9 (Section 
10.9) Abbreviations  Added COVID-19 For clarification 
Section 11 References The European Parliament and the 
Council of the European Union Reference added for information 
 
Protocol version 4.0, including protocol amendment no. 1, 2 and 3: 28 April 2021, Croatia and 
Germany 
This amendment is considered to be non-substantial based on the criteria set for th in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union,1 because 
it neither significantly impacts the safety nor phys ical/mental integrity of subjects nor the scientific 
value of the trial. 
For Croatia and Germany, co-participation in COVID-19 trials is not allowed due to local 
requirements, and not allowing co-participation in COVID-19 trials does not affect patient safety. 
Overall rationale for preparing protocol, version 4.0: 
The overall rationale for the changes implemented  in the amended protocol is to address local 
requirements in Croatia and Germany. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 90 of 93 
 
Section # and name Description of change Brief rationale 
5.2 Exclusion criteria Updated to include a reference to 
country -specific requirements for 
Croatia and Germany  Co-participation in COVID-19 trials 
is not allowed in Croatia and 
Germany d ue to local requirements. 
6.5 Concomitant medications Updated to include a reference to 
country -specific requirements for 
Croatia and Germany  Co-participation in COVID-19 trials 
is not allowed in Croatia and Germany due to local requirements. 
7.1 Discontinuation of trial treatment Updated to include a reference to 
country -specific requirements for 
Croatia and Germany  Co-participation in COVID-19 trials 
is not allowed in Croatia and Germany due to local requirements. 
10.8 Appendix 8: Country-specific 
requirements  Requirements for Croatia and 
Germany updated to disallow co -
participation in clinical trials 
evaluating approved or non -
approved investigational medicinal 
products for the prevention or treatment of COVID
-19 disease or 
COVID -19 postinfectious 
conditions. Accordingly, exclusion 
criterion #15, use of concomitant medications related to COVID
-19 
and discontinuation of trial treatment 
criterion #5 are not applicable for 
Croatia and Germany.  Co-participation in COVID-19 trials 
is not allowed in Croatia and 
Germany  due to local requirements. 
 
Protocol version 5.0, including protocol ame ndment no. 1, 2, 3 and 4: 04 June 2021, global 
This amendment is considered to be non-substantial based on the criteria set for th in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union,1 because 
it neither significantly impacts the safety nor phys ical/mental integrity of subjects nor the scientific 
value of the trial. 
Overall rationale for preparing protocol, version 5.0: 
The overall rationale for the changes implemented  in the amended protocol is to include an 
unblinded monitor. 
Section # and name Description of change Brief rationale 
6.3 Measures to minimise bias: 
Randomisation and blinding  Addition of an unblinded monitor To clarify monitoring responsibilities 
10.1.8.2 Monitoring Addition of an unblinded monitor To clarify monitoring responsibilities CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 91 of 93 
 
Protocol version 6.0, including protocol ame ndment no. 1, 2, 3, 4 and 5: 01 February 2022 
This amendment is considered to be non-substantial based on the criteria set for th in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union,1 because 
it neither significantly impacts the safety nor phys ical/mental integrity of subjects nor the scientific 
value of the trial. 
Overall rationale for preparing protocol, version 6.0: 
The overall rationale for the changes implemented in the amended protocol is to include the 
possibility of performing partial DBL and to update the text related to reconciliation process to 
include risk based reconciliation. 
Section # and name Description of change Brief rationale 
9.4 statistical analysis, 9.4.3.2 supportive 
secondary endpoints , 9.4.5.1 
pharmacokinetic modelling, 9.7 r eporting 
of the main part of the trial  
 Addition of partial DBL text The possibility of performing a 
partial DBL is implemented to support potential earlier access of oral semaglutide 25 and 50 mg to 
the patient population expected to 
benefit from higher doses. 
 
6.2 
preparation/handling/st orage/accountability Text with respect to reconciliation 
process is updated as below:  
"Destruction of trial products can 
be performed on an ongoing basis 
and will be done according to 
local procedures after 
accountability is finalised by the site and 
reconciled by the 
monitor . 
Destruction of trial product must 
be documented in the IWRS."  
Deleted bold  text from the above 
bullet point  This text was misleading in 
relation to the reconciliation process set up for PIONEER PLUS as risk based reconciliation 
is used for this trial.
 
10.1.8.2 Monitoring  The last bullet text regarding 
reconciliation process has been updated i.e.  "An unblinded 
monitor will reconcile trial 
product accountability" was 
updated to "An unblinded monitor 
will be responsible for the reconciliation process set up for thi
s trial." This text was misleading in 
relation to the reconciliation process set up for PIONEER 
PLUS as risk based reconciliation 
is used for this trial.
 CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 92 of 93 
 
 11 "#  
1. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council  of 4 April 2001 on the approximation of the 
laws, regulations and administrative provisions  of the member states relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. 2001. 
2. Novo Nordisk A/S. Rybelsus
Â® (semaglutide tablets), US Prescribing Information. September 
2019. 
3. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. 
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) a nd the European Association for the Study of 
Diabetes (EASD). Diabetes Care. 2018;41(12):2669-701. 
4. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 Update to: 
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) a nd the European Association for the Study of 
Diabetes (EASD). Diabetes Care. 2020;43(2):487-93. 
5. Novo Nordisk A/S. Investigator's Brochure, Oral semaglutide for Type 2 Diabetes, Project 
NN9924 (ed. 11). 31 July 2019. 
6. Novo Nordisk A/S. Rybelsus
Â® (oral semaglutide), EU Summary of Product Characteristics 
(SmPC). 03 Apr 2020. 
7. Novo Nordisk A/S. RybelsusÂ® (oral semaglutide), US Prescribing Information (PI). 20 Sep 
2019. 
8. Meier J. Efficacy of oral semaglutide accordi ng to baseline HbA1c: an exploratory subgroup 
analysis of the PIONEER trial programme [Internet]. EASD Barcelona 2019, virtual 
meeting, oral presentation #51, Session: Semaglutide: ingested or injected. 2019 [cited 2020 21 Apr]. 
9. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification 
of acute pancreatitis-2012: revision of the Atlanta classification and definitions by 
international consensus. Gut. 2013;62(1):102-11. 
10. .C62@$N92@@6<?.186;!"2?;.;,$.A562B$6;4?<;2 2A.9 Management 
of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-701. 
11. Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical 
approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biometrical Journal. 2011;53(6):894-913. 
12. Rohmeyer K, Klinglmueller F. gMCP: Graph Based Multiple Test Procedures. R package 
version 0.8-8. 10/3/2014 2014. 
13. Little RJA, Rubin DB. Statistical analysis with missing data. New York: Wiley. 1987. xiv, 
278 p. p. 
14. World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical 
Research Involving Human Subjects. Last amended by the 64th WMA General Assembly, Fortaleza, Brazil. October 2013. 
15. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R2), Current 
step 4 version. 09 Nov 2016. 
16. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351(12):1250-1. CONFIDENTIAL
Protocol 
CONFIDENTIAL Date: 16 September 2022 Novo Nordisk 
Trial ID: NN9924-4635 Version: 7.0 
      Status: Final 
      Page: 93 of 93 
 
 17. Food and Drug Administration. Food and Drug  Administration Amendments Act of 2007 as 
amended by the Final Rule "Clinical Tria ls Registration and Results Information 
Submission". 21 September 2016. 
18. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of th e Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, article 57. 30 April 2004. 
19. The European Parliament and the Council of the European Council. Regulation (EC) No 
1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use a nd amending Regulation (EEC) No 1768/92, 
Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, article 41. 
Official Journal of the European Communities. 27 Dec 2006. 
20. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholar ly Work in Medical Journals; current version 
available at www.icmje.org. 
21. International Hypoglycaemia Study Group. Glucos e concentrations of less than 3.0 mmol/l 
(54 mg/dl) should be reported in clinical tria ls: a joint position statement of the American 
Diabetes Association and the Europian Association for the Study of Diabetes. Diabetologia. 2017;60(1):3-6. 
22. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in 
Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55-S64. 
23. Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, et al. ISPAD 
Clinical Practice Consensus Guidelines 2018: Assessment and management of 
hypoglycemia in children and adolescents wi th diabetes. Pediatr Diabetes. 2018;19 Suppl 
27:178-92. 
24. Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, et al. 
Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American  Association of Clinical Endocrinologists, 
the American Association of Diabetes Educators , the American Diabetes Association, the 
Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable 
Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 2017;40(12):1622-30. 
25. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International 
Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-40. 
26. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabe tes Care. 2013;36(5):1384-95. 
27. US Food and Drug Administration. Guidan ce for Industry. Patient-Reported Outcome 
Measures: Use in Medical Product Development to Support Labeling Claims. December 2009. 
28. Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-42. CONFIDENTIAL